[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5812
1. Møller AK, Pedersen KD, Gothelf A, Daugaard G: Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol; 2010 May;49(4):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
  • BACKGROUND: The present study was conducted to evaluate the efficacy and toxicity of a combination of paclitaxel, cisplatin and gemcitabine in patients with carcinoma of unknown primary site (CUP).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bone Marrow / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Paclitaxel / administration & dosage. Risk Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397773.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Marqués E, Jiménez C, Manrique A, Vallejo GH, Clemares M, Ortega P, Moreno E: Development of lymphoproliferative disease after liver transplantation. Transplant Proc; 2008 Nov;40(9):2988-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of lymphoproliferative disease after liver transplantation.
  • INTRODUCTION: Malignancies are a serious long-term complication among liver transplant recipients, with an overall incidence of 4.5%-15%.
  • The aim of this study was to analyze risk factors for PTLD and survival after orthotopic liver transplantation (OLT) compared with solid tumors.
  • PATIENTS AND METHODS: We undertook a retrospective review of the clinical histories of adult patients who underwent OLT between July 1986 and February 2001, and who had been followed until 2005.
  • This study comprised 528 adult recipients who survived more than 2 months after OLT.
  • [MeSH-major] Liver Transplantation / adverse effects. Lymphoproliferative Disorders / epidemiology
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / epidemiology. Cyclosporine / adverse effects. Cyclosporine / therapeutic use. Female. Graft Rejection / epidemiology. Graft Rejection / prevention & control. Humans. Immunosuppression / methods. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Male. Retrospective Studies. Risk Factors. Skin Neoplasms / epidemiology. Survival Analysis. Survivors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010169.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


3. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY: Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol; 2005 Aug 14;11(30):4655-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.
  • AIM: To investigate the clinical values of serum free insulin-like growth factor II (IGF-II) levels and IGF-II mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood for diagnosis of HCC and monitoring of extrahepatic metastasis.
  • METHODS: Total RNAs were extracted from HCC tissues or peripheral blood mononuclear cells from patients with HCC, liver diseases devoid of cancer, non-hepatic tumors, and healthy controls, respectively.
  • Serum free IGF-II levels in patients with different liver diseases were analyzed by an enzyme-linked immunosorbent assay.
  • The serum free IGF-II levels were significantly higher in HCC than those in chronic hepatitis or liver cirrhosis.
  • The positive frequency of circulating IGF-II mRNA was 34.2% in HCC, no amplified fragment was found in other liver diseases, extrahepatic tumors, and normal controls, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Insulin-Like Growth Factor II / genetics. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Molecular Sequence Data

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094705.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ PMC4615406
  •  go-up   go-down


Advertisement
4. Yu ZX, Xia GP, Hu WH, Chen W, Li XB, Chen HD, Lin LZ, Deng ZX, Cai B, Weng ZL: [Etiology, diagnosis and management of spontaneous per renal hemorrhage]. Zhonghua Yi Xue Za Zhi; 2006 Jan 3;86(1):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The underlying disease of SPH included angiomyolipoma (18 cases), renal cell carcinoma (7 cases), kidney cyst (2 cases), renal artery aneurysm (3 cases), rupture of renal artery aneurysm accompanied with pregnancy (2 cases), renal pheochromocytoma (3 cases 2 of which accompanied with pregnancy), congenital stricture of pelvic ureter junction (1 case), and liver cancer (1 case).
  • The most common underlying diseases were nephrogenic (96%) with angiomyolipoma ranking first (54%) followed by renal cell carcinoma (21%).
  • [MeSH-minor] Adolescent. Adult. Aged. Aneurysm / complications. Angiography, Digital Subtraction. Angiomyolipoma / complications. Anticoagulants / therapeutic use. Child. Female. Humans. Kidney Neoplasms / complications. Kidney Transplantation. Male. Middle Aged. Pregnancy. Renal Artery / pathology. Renal Dialysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606534.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


5. Chekmareva IA, Vtiurin BV, Dubova EA, Shchegolev AI: [Ultrastructural characteristics of hepatocellular carcinoma]. Arkh Patol; 2010 May-Jun;72(3):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrastructural characteristics of hepatocellular carcinoma].
  • The histological study diagnosed low-, moderate, and high-grade hepatocellular carcinoma in 5, 12, 5 patients, respectively.
  • The high-grade type was characterized by the signs of significant cell structural and functional rearrangement; changes in the number, sizes, and shape of intracellular masses (a nucleus, mitochondria, endoplasmic network, lysosomes).
  • [MeSH-major] Carcinoma, Hepatocellular / ultrastructure. Liver Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Female. Humans. Liver / ultrastructure. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734825.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


6. Chen Y, Xie D, Yin Li W, Man Cheung C, Yao H, Chan CY, Chan CY, Xu FP, Liu YH, Sung JJ, Kung HF: RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett; 2010 Nov 1;297(1):109-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo.
  • The function of EZH2 in tumorigenesis and liver metastasis of pancreatic cancer has never been elucidated in vivo.
  • Knock-down of EZH2 inhibited liver metastasis of pancreatic cancer in vivo.
  • EZH2 has a crucial role in tumor growth and liver metastasis of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / therapy. DNA-Binding Proteins / genetics. Genetic Therapy / methods. Liver Neoplasms / prevention & control. Pancreatic Neoplasms / therapy. RNA Interference. Transcription Factors / genetics. Tumor Burden
  • [MeSH-minor] Adult. Aged. Animals. Cell Differentiation. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Staging. Polycomb Repressive Complex 2. Time Factors. Transfection. Up-Regulation. Xenograft Model Antitumor Assays


7. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, Dematteo RP: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg; 2009 Apr;249(4):617-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma.
  • OBJECTIVE: To determine if the degree of blood loss during resection of hepatocellular carcinoma (HCC) is predictive of recurrence and long-term survival.
  • BACKGROUND: Several studies have addressed the impact of blood transfusion on survival and recurrence after liver resection for HCC.
  • [MeSH-major] Blood Loss, Surgical / mortality. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Hepatectomy / adverse effects. Hepatectomy / methods. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Postoperative Complications / mortality. Predictive Value of Tests. Probability. Prognosis. Registries. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300227.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Mahtab MA, Rahman S, Khan M, Kamal M, Mamun AA, Karim MF: Viral load speaks little about toll on liver. Hepatobiliary Pancreat Dis Int; 2007 Oct;6(5):483-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral load speaks little about toll on liver.
  • It has been estimated that this virus is responsible for 10%-35% cases of acute viral hepatitis, 35.7% cases of fulminant hepatic failure, 33.3%-40.5% cases of chronic hepatitis and 46.8% cases of hepatocellular carcinoma in Bangladesh.
  • The aim of this study is to compare the correlation between HBV DNA load and grade and stage of liver disease in patients with chronic hepatitis B (CHB).
  • METHODS: Percutaneous liver biopsies done in 159 CHB patients revealed 62.9% (100 patients) had wild type HBV infection and the rest 37.1% (59) had pre-core/core promoter mutant HBV infection.
  • CONCLUSIONS: The study shows that high HBV DNA load does not correlate with necro-inflammatory activity or extent of fibrosis in the liver in patients with either wild type or pre-core mutant type CHB.
  • [MeSH-major] DNA, Viral / analysis. Hepatitis B virus / genetics. Hepatitis B, Chronic / virology. Liver / virology. Viral Load
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Prospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897910.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


9. Laca L, Olejnik J, Vician M, Grandtnerova B, Zahradnik V: The effects of occlusive techniques on the short-term prognosis after liver resections. Hepatogastroenterology; 2006 Jul-Aug;53(70):576-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of occlusive techniques on the short-term prognosis after liver resections.
  • BACKGROUND/AIMS: Anatomic liver resection can be performed without vascular occlusion, but controlling blood loss during liver parenchyma dissection by compression or clamping of vessels in the liver hilus is almost the rule.
  • The aim of this study is to assess the negative consequences of different types of occlusion techniques used during liver parenchyma dissection.
  • METHODOLOGY: From 2001 to 2003, 43 anatomical liver resections were performed in patients with primary and metastatic tumors.
  • RESULTS: Within the continuous occlusion group that lasted longer than 20 minutes (37 +/- 14 min) increase in levels of bilirubin and liver enzymes and decrease of prothrombin time were noted as compared to the group with occlusion shorter than 20 minutes and to the group with intermittent occlusion over 20 minutes (34 +/- 5 min).
  • CONCLUSIONS: From results issued, it can be seen that using intermittent occlusion during liver parenchyma dissection lasting longer than 20 minutes causes less ischemic-reperfusion injury in the remaining liver parenchyma than by using continual occlusion.
  • [MeSH-major] Carcinoma / surgery. Hepatectomy. Liver / blood supply. Liver Neoplasms / surgery. Reperfusion Injury / prevention & control. Tourniquets
  • [MeSH-minor] Adult. Aged. Constriction. Female. Humans. Male. Middle Aged. Postoperative Period. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995465.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Ishizaki Y, Yoshimoto J, Miwa K, Sugo H, Kawasaki S: Safety of prolonged intermittent pringle maneuver during hepatic resection. Arch Surg; 2006 Jul;141(7):649-53; discussion 654
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has recently been demonstrated that the liver parenchyma is more tolerant to intermittent pedicular clamping than to continuous pedicular clamping.
  • PATIENTS: Resections were performed for metastatic carcinoma in 19 patients, hepatocellular carcinoma in 7 patients, hilar bile duct carcinoma in 3 patients, intrahepatic cholangiocarcinoma in 1 patient, combined hepatocellular carcinoma and cholangiocarcinoma in 1 patient, undifferentiated embryonal sarcoma in 1 patient, carcinoid tumor in 1 patient, and benign mucinous cystic tumor in 1 patient.
  • Twenty-eight patients had histologically normal underlying liver parenchyma; 6 patients had chronic hepatitis or cirrhosis.
  • RESULTS: No red blood cell transfusions were required in group 1; blood transfusions were needed for only 3 patients in group 2.
  • CONCLUSIONS: Prolonged intermittent pedicular clamping is a useful maneuver in hepatectomy when resection is difficult or prolonged or when the liver parenchyma is abnormal.
  • [MeSH-major] Hepatectomy / methods. Ischemia / physiopathology. Liver / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Constriction. Female. Follow-Up Studies. Humans. Intraoperative Period. Liver Circulation. Liver Function Tests. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847234.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST: Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg; 2008 Jan;12(1):183-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.
  • BACKGROUND: Radiofrequency ablation (RFA) is an effective local ablation therapy for hepatocellular carcinoma (HCC) with favorable long-term outcome.
  • Among them, 117 patients (56%) had unresectable HCC because of bilobar disease, poor liver function, and/or high medical risk for resection; whereas 92 patients (44%) underwent RFA as the primary treatment for small resectable HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Follow-Up Studies. Hong Kong / epidemiology. Humans. Laparoscopy / methods. Male. Middle Aged. Morbidity / trends. Neoplasm Invasiveness. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1195-202 [8826940.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):616-28 [15965731.001]
  • [Cites] Dig Surg. 1999;16(6):459-67 [10805544.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):791-6 [13129558.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1364-73 [16240062.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1201-9 [15690326.001]
  • [Cites] Eur Radiol. 2001;11(6):914-21 [11419162.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Gut. 2005 Aug;54(8):1151-6 [16009687.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):759-68 [8751696.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1219-22 [8983610.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):41-52 [15777889.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5 Suppl):S316-21 [16632694.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):181-90 [16490897.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1618-24 [8194710.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):440-7 [16470712.001]
  • (PMID = 17874276.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Kim KW, Lee JM, Klotz E, Park HS, Lee DH, Kim JY, Kim SJ, Kim SH, Lee JY, Han JK, Choi BI: Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma. Radiology; 2009 Feb;250(2):425-434
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma.
  • PURPOSE: To investigate the diagnostic value of quantitative determination and three-dimensional color mapping of the arterial enhancement fraction (AEF) of the liver for the detection of hepatocellular carcinoma (HCC).
  • Eighty-two patients (mean age, 56.2 years +/- 10.7 [standard deviation]), 69 men (mean age, 57.1 years +/- 10.0) and 13 women (mean age, 51.6 years +/- 13.6), were followed-up for HCC or liver cirrhosis by using available multiphasic multidetector computed tomographic (CT) scans.
  • Quantitative AEF color maps (the ratio of the attenuation increment during the arterial phase to the attenuation increment during the portal venous phase) of the whole liver were created from routine CT images by using prototypic software.
  • RESULTS: The mean AEF of HCCs (75.6 +/- 13.3) was significantly higher than that of liver parenchyma (23.4 +/- 8.2) (P < .001).
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Liver Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Color. Contrast Media. Female. Humans. Male. Middle Aged. ROC Curve. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188314.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


13. Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH, Yu JC: Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg; 2010 Aug;200(2):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria.
  • BACKGROUND: The decision to perform liver transplantation (LT) or liver resection (LR) for patients with hepatocellular carcinoma (HCC) who are beyond the Milan criteria remains controversial.
  • RESULTS: Patients who underwent LR group were significantly older, had a lower TNM stage, and were more likely to have unilateral disease and noncirrhotic liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Patient Selection. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20122677.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Huang J, Karakucuk V, Levitsky LL, Rhoads DB: Expression of HNF4alpha variants in pancreatic islets and Ins-1 beta cells. Diabetes Metab Res Rev; 2008 Oct;24(7):533-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocyte nuclear factor (HNF4alpha) is a nuclear receptor essential for endodermal differentiation and cell functions in the adult pancreas, liver, and other tissues.
  • Because some variants lack the N-terminal activation function 1 (AF-1) and/or C-terminal inhibitory F domain, defining their tissue-specific regulation and function is important for understanding pancreatic beta cell behaviour.
  • METHODS: Expression of HNF4alpha variants in islets, rat Ins-1 insulinoma cells, and human Hep3B hepatocellular carcinoma cells was assessed using a long-range reverse transcription-polymerase chain reaction (RT-PCR) strategy capable of recognizing each combination of mRNA termini.
  • RESULTS: Mouse islets and both cell lines express HNF4alpha9, which lacks both AF-1 and the F domain.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18561282.001).
  • [ISSN] 1520-7552
  • [Journal-full-title] Diabetes/metabolism research and reviews
  • [ISO-abbreviation] Diabetes Metab. Res. Rev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK040561-13; United States / NIDDK NIH HHS / DK / P30 DK040561; United States / NIDDK NIH HHS / DK / P30 DK040561-13
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatocyte Nuclear Factor 4; 0 / RNA, Messenger
  •  go-up   go-down


15. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA: Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer; 2005 Oct;6(4):354-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, we describe the successful treatment of a woman at 27 weeks of pregnancy with recurrent HER2/neu-overexpressing breast cancer who was symptomatic from multiple liver metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Female. Humans. Liver / pathology. Lymphatic Metastasis. Magnetic Resonance Imaging. Pregnancy. Trastuzumab. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives


16. Morohashi S, Morohashi H, Saito C, Odagiri H: [A case of recurrent breast cancer with liver metastasis responding to exemestane]. Gan To Kagaku Ryoho; 2009 May;36(5):811-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer with liver metastasis responding to exemestane].
  • We report a woman in her 30s who developed a right breast tumor 10 years after undergoing mastectomy for invasive ductal carcinoma of the left breast.
  • She underwent modified radical mastectomy for the right breast cancer, which was diagnosed histologically as invasive ductal carcinoma with metastasis to the axillary lymph nodes.
  • Because of the risk of recurrence, she received postoperative systemic adjunctive chemotherapy using CMF, but this had to be withdrawn because of liver toxicity.
  • After a disease-free interval of 34 months, liver metastasis appeared, and so tamoxifen was changed to exemestane.
  • [MeSH-major] Androstadienes / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Female. Humans. Recurrence. Tomography, X-Ray Computed


17. Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K: Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother Pharmacol; 2008 Nov;62(6):959-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear.
  • METHODS: Twenty-one adult Japanese LC patients with aHCC were treated by intra-arterial combination chemotherapy.
  • The control group was composed of 20 adult Japanese patients with chronic hepatitis C diagnosed from examination of liver biopsy specimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carcinoma, Hepatocellular / drug therapy. Drug Monitoring / methods. Liver Neoplasms / drug therapy. Lymphocyte Count. Th1 Cells / drug effects. Th2 Cells / drug effects
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cisplatin / pharmacology. Female. Fluorouracil / administration & dosage. Fluorouracil / pharmacology. Hepatitis C, Chronic / immunology. Hepatitis, Viral, Human / complications. Hepatitis, Viral, Human / immunology. Humans. Infusions, Intra-Arterial. Interferon-gamma / blood. Interleukin-4 / blood. Leucovorin / administration & dosage. Leucovorin / pharmacology. Liver Cirrhosis / complications. Liver Cirrhosis / immunology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259753.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / IL4 protein, human; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Adler M, De Pauw F, Vereerstraeten P, Fancello A, Lerut J, Starkel P, Van Vlierberghe H, Troisi R, Donckier V, Detry O, Delwaide J, Michielsen P, Chapelle T, Pirenne J, Nevens F: Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl; 2008 Apr;14(4):526-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system.
  • Although hepatocellular carcinoma (HCC) has become a recognized indication for liver transplantation, the rules governing priority and access to the waiting list are not well defined.
  • Assessing the value of the pretransplantation staging by imaging compared to explant pathology revealed 34% accuracy, absence of carcinoma in 8.3%, overstaging in 36.2%, and understaging in 10.4%.
  • Allocation rules for HCC should consider not only tumor characteristics but also the degree of liver impairment.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Health Care Rationing / methods. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data. Resource Allocation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Europe. Female. Humans. Male. Middle Aged. Patient Selection. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 AASLD.
  • (PMID = 18383082.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XY, Huang JF, Lencioni R: Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology; 2009 Nov;253(2):552-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy.
  • PURPOSE: To investigate whether ethanol ablation by using a multipronged needle delivery system (multipronged ethanol ablation) could eradicate hepatocellular carcinoma (HCC) up to 5.0 cm in diameter with a single-session high-dose strategy.
  • One hundred forty-one patients (125 men, 16 women; mean age, 53 years; range, 27-76 years) with 164 primary or recurrent HCC ranging from 1.3 to 5.0 cm in diameter (mean, 2.9 cm +/- 0.9) were treated with high-dose multipronged ethanol ablation.
  • Primary technique effectiveness (PTE) (complete ablation within two sessions), local tumor progression (LTP), and complications after the treatment were observed.
  • [MeSH-major] Ethanol / administration & dosage. Injections, Intralesional / instrumentation. Liver Neoplasms / therapy. Needles
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / therapy. Carcinoma, Hepatocellular / ultrasonography. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19709992.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 3K9958V90M / Ethanol
  •  go-up   go-down


20. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I, Uemoto S: Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.
  • PURPOSE: To investigate the diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) for prediction of tumor differentiation, P-glycoprotein (P-gp) expression, and outcome in hepatocellular carcinoma (HCC) patients.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Fluorodeoxyglucose F18. Gene Expression Regulation, Neoplastic. Liver Neoplasms / metabolism. P-Glycoprotein / biosynthesis. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Risk

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255262.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Schindera ST, Soher BJ, Delong DM, Dale BM, Merkle EM: Effect of echo time pair selection on quantitative analysis for adrenal tumor characterization with in-phase and opposed-phase MR imaging: initial experience. Radiology; 2008 Jul;248(1):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Single-breath-hold IP and OP 3.0-T MR images in 21 patients (14 women, seven men; mean age, 63 years) with 23 adrenal tumors (16 adenomas, six metastases, one adrenocortical carcinoma) were reviewed.
  • However, with scheme B, no overlap in the adrenal gland SI-to-liver SI ratio between adenomas and nonadenomas was seen (P < .05).
  • With scheme B, no overlap in adrenal gland SI index-to-liver SI index ratio between adenomas and nonadenomas was seen (P < .05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18566172.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tung CB, Tung CF, Yang DY, Hu WH, Hung DZ, Peng YC, Chang CS: Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. Hepatogastroenterology; 2005 Sep-Oct;52(65):1347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia.
  • The aim of this study was to evaluate the characteristics of extremely high levels of ALP in adult patients as a manifestation of bacteremia.
  • [MeSH-major] Alkaline Phosphatase / blood. Bacteremia / enzymology. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / enzymology. Bile Ducts, Intrahepatic. Bone Neoplasms / enzymology. Bone Neoplasms / secondary. Carcinoma, Hepatocellular / enzymology. Cholangiocarcinoma / enzymology. Cholestasis / enzymology. Escherichia coli Infections / enzymology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201071.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


23. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N: AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol; 2010 Dec;45(12):1272-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ-carboxy prothrombin (DCP), and Golgi protein-73 (GP73) have been used or proposed as tumor markers for hepatocellular carcinoma (HCC).
  • The increased DCP value was, or tended to be, associated with a larger tumor, vascular invasion, intrahepatic metastases, and a lower grade of tumor cell differentiation.
  • Although similar associations were found between AFP and vascular invasion as well as a lower grade of tumor cell differentiation, no such relationship was found with AFP-L3.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Membrane Proteins / blood. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Prospective Studies. Protein Precursors / blood. Prothrombin. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome. Young Adult. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2009 Jul;137(1):110-8 [19362088.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):858-66 [18202893.001]
  • [Cites] Clin Chim Acta. 1993 Jan 31;214(1):3-12 [7680970.001]
  • [Cites] Hepatology. 2009 May;49(5):1602-9 [19291786.001]
  • [Cites] Ann Clin Biochem. 2009 Jan;46(Pt 1):38-43 [19008260.001]
  • [Cites] Anal Biochem. 2009 May 15;388(2):306-11 [19250915.001]
  • [Cites] Med Oncol. 2010 Jun;27(2):339-45 [19399652.001]
  • [Cites] Hepatol Int. 2008 Mar;2(1):17-30 [19669276.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):91-9 [15757806.001]
  • [Cites] J Hepatol. 2005 Dec;43(6):1007-12 [16137783.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):650-4 [10086646.001]
  • [Cites] J Hepatol. 2008 Aug;49(2):223-32 [18571271.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):802-7 [11022927.001]
  • [Cites] J Gastroenterol. 2007 Dec;42(12):962-8 [18085353.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1032-8 [10460639.001]
  • [Cites] Hepatol Res. 2008 Jan;38(1):37-51 [18039202.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5419-23 [7693340.001]
  • [Cites] Liver Int. 2005 Aug;25(4):848-53 [15998436.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):2038-43 [16848811.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8 [18422961.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):311-6 [17326126.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] N Engl J Med. 1984 May 31;310(22):1427-31 [6201741.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):394-402; quiz 267 [17368240.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Oncology. 2007;72 Suppl 1:52-7 [18087182.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2795-804 [19669841.001]
  • [Cites] Hepatology. 2003 May;37(5):1114-21 [12717392.001]
  • [Cites] Am J Gastroenterol. 1994 Dec;89(12):2222-6 [7526679.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Jul;17(7):772-8 [12121507.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2196-205 [17617202.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):145-59 [11218912.001]
  • [Cites] Semin Surg Oncol. 1993 Jul-Aug;9(4):298-304 [8210909.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6115-9 [16273636.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Lancet. 1985 Dec 14;2(8468):1353-4 [2415789.001]
  • [Cites] Cancer. 1994 May 15;73(10):2464-71 [7513601.001]
  • (PMID = 20625772.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / GOLM1 protein, human; 0 / Membrane Proteins; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


24. Garko SB, David OS, Mohammed T, Isah MS, Bakari AG, Oguntayo AO, Shehu MS, Aminu SM: Hepatocellular carcinoma in pregnancy. Ann Afr Med; 2009 Oct-Dec;8(4):284-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in pregnancy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Analgesia. Female. Hepatitis B Surface Antigens / analysis. Humans. Infant, Newborn. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139556.001).
  • [ISSN] 0975-5764
  • [Journal-full-title] Annals of African medicine
  • [ISO-abbreviation] Ann Afr Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


25. Linder S, Boström L, Nilsson B: Pancreatic cancer in sweden 1980-2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg; 2006 May;10(5):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients treated for pancreatic carcinoma in Sweden during 1980-2000 were identified in the Swedish Hospital Discharge Register and the Cancer Register.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Digestive System Surgical Procedures / methods. Digestive System Surgical Procedures / trends. Female. Humans. Length of Stay. Male. Middle Aged. Palliative Care / methods. Palliative Care / trends. Sweden / epidemiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):164-84 [8696550.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315 [14662530.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):484-9 [10947015.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):527-35 [15057558.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):18-24 [9208956.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Dig Surg. 2000;17(2):143-6 [10781977.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):137-48 [12170018.001]
  • [Cites] Int J Pancreatol. 1997 Jun;21(3):219-24 [9322120.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):823-30 [10896377.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):894-902; discussion 902-5 [14631226.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gastrointest Surg. 2000 Sep-Oct;4(5):443-52 [11077317.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2609-15 [11569683.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):310-2 [11967685.001]
  • [Cites] J Clin Gastroenterol. 2004 Jan;38(1):59-67 [14679329.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Lancet. 1986 Jan 11;1(8472):69-71 [2417075.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):30-6 [12576921.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6 Suppl):S213-7 [12447270.001]
  • [Cites] Eur J Surg. 2002;168(6):339-44 [12428871.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):8-20 [1371087.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):161-7 [12894006.001]
  • [Cites] Am Surg. 2001 Mar;67(3):270-5; discussion 275-6 [11270888.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):128-32; discussion 132-3 [7680512.001]
  • [Cites] Dig Liver Dis. 2002 Oct;34(10):723-31 [12469800.001]
  • [Cites] Radiology. 2002 Jul;224(1):34-41 [12091659.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):125-33 [2827228.001]
  • (PMID = 16713540.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sano T, Izuishi K, Takebayashi R, Masaki T, Suzuki Y: Operative management of solitary intra-abdominal recurrence of hepatocellular carcinoma. Surgery; 2010 Feb;147(2):311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of solitary intra-abdominal recurrence of hepatocellular carcinoma.
  • [MeSH-major] Abdominal Neoplasms / secondary. Abdominal Neoplasms / surgery. Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945131.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


27. Chen L, Li DC, Zhu Y: [Exploring the significance of NET-1 gene in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):596-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Exploring the significance of NET-1 gene in hepatocellular carcinoma].
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468313.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NET1 protein, human; 0 / Oncogene Proteins
  •  go-up   go-down


28. Pan CC, Huang ZL, Li W, Zhao M, Zhou QM, Xia JC, Wu PH: Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer; 2010 Jun;29(6):596-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
  • BACKGROUND AND OBJECTIVE: In patients with hepatocellular carcinoma (HCC) receiving potentially curative minimally invasive therapy, autologous cytokine-induced killer (CIK) cells were used to reduce recurrence.
  • In the study group, CIK cells were transfused intravenously or via common hepatic arteries every week for at least 4 times, and the T-lymphocyte subset data before and after CIK cell infusions was examined by flow cytometry.
  • After CIK cell infusions, the downtrend of the AFP level was observed in the study group and not in the control group.
  • After CIK cell infusions, the percent of CD3+CD4+ T cells and CD4+ /CD8+ T cells increased from 28.1+/-5.9% and 0.9+/-0.3% to 32.7+/-3.6% and 1.2+/-0.2% (P<0.001 and=0.004, respectively), while the percent of CD3+CD8+ T cells decreased from 32.9+/-8.4% to 28.8+/-2.2% (P=0.046).
  • Serum AFP decrease after CIK cell treatment may serve as a useful marker for predicting immunotherapy clinical outcome in patients with HCC undergone curative minimally invasive therapy.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Cytokine-Induced Killer Cells / transplantation. Liver Neoplasms / therapy. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. CD4-CD8 Ratio. Catheter Ablation. Chemoembolization, Therapeutic. DNA, Viral / metabolism. Female. Follow-Up Studies. Hepatitis B virus / genetics. Humans. Immunotherapy, Adoptive. Male. Middle Aged. Neoplasm Recurrence, Local. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507732.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / alpha-Fetoproteins
  •  go-up   go-down


29. Liu Q, Chen J, Li H, Liang B, Zhang L, Hu T: Hepatocellular carcinoma with bile duct tumor thrombi: correlation of magnetic resonance imaging features to histopathologic manifestations. Eur J Radiol; 2010 Oct;76(1):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma with bile duct tumor thrombi: correlation of magnetic resonance imaging features to histopathologic manifestations.
  • PURPOSE: This study was to analyze the magnetic resonance imaging (MRI) features of hepatocellular carcinoma (HCC) with bile duct tumor thrombi, and explore their correlations to histopathology to improve the accuracy of diagnosis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Hepatocellular / diagnosis. Cholangiopancreatography, Magnetic Resonance / methods. Jaundice, Obstructive / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Liver Function Tests. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19501994.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


30. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, Bekaii-Saab TS: A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology; 2010;78(3-4):210-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
  • OBJECTIVES: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20424492.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


31. Eguchi S, Ijtsma AJ, Slooff MJ, Porte RJ, de Jong KP, Peeters PM, Gouw AS, Kanematsu T: Outcome and pattern of recurrence after curative resection for hepatocellular carcinoma in patients with a normal liver compared to patients with a diseased liver. Hepatogastroenterology; 2006 Jul-Aug;53(70):592-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and pattern of recurrence after curative resection for hepatocellular carcinoma in patients with a normal liver compared to patients with a diseased liver.
  • BACKGROUND/AIMS: The purpose of this study was to investigate whether differences existed in demography and outcome after resection for hepatocellular carcinoma (HCC) in patients with a normal liver compared to patients with a diseased liver.
  • METHODOLOGY: Twenty-seven Caucasian patients with HCC in a histologically proven normal liver (NL group) in the Netherlands and 141 Asian patients with HCC in a diseased liver (DL group) in Japan underwent a curative liver resection.
  • Extrahepatic recurrences were more frequent after curative resection for HCC in a normal liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Disease-Free Survival. European Continental Ancestry Group. Female. Hepatectomy. Humans. Japan / epidemiology. Liver / pathology. Liver / surgery. Male. Middle Aged. Netherlands / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995469.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Widjaja D, Yarlagadda S, Singu BS, Loganathan RS, Blum S, Bloom A, Remy P: Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. J Natl Med Assoc; 2007 Apr;99(4):384-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In the United States, among patients with hepatocellular carcinoma (HCC) and portal hypertension from chronic hepatitis-B virus infection, 44% were Hispanic and 28% were African American.
  • One-hundred-forty-six (87%) patients without decompensated liver cirrhosis were not treated owing to the following reasons: normal alanine aminotransferase level (86%), active injection drug or heavy alcohol use (9%), lack of health insurance coverage (3%) and noncompliance with visits during the evaluation period (2%).
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / contraindications. Adenine / therapeutic use. Adolescent. Adult. Female. Humans. Insurance Coverage. Interferons / contraindications. Interferons / therapeutic use. Lamivudine / contraindications. Lamivudine / therapeutic use. Liver Cirrhosis / diagnosis. Liver Cirrhosis / ethnology. Male. Mass Screening / methods. Mass Screening / utilization. Middle Aged. New York City / epidemiology. Organophosphonates / contraindications. Organophosphonates / therapeutic use. Pilot Projects. Refusal to Treat. Risk Factors. Utilization Review

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Jan;39(1):81-9 [14752826.001]
  • [Cites] Singapore Med J. 2004 Sep;45(9):423-6 [15334285.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] J Infect Dis. 2002 Mar 15;185(6):713-9 [11920288.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1225-41 [11732013.001]
  • [Cites] Inquiry. 2006 Fall;43(3):231-54 [17176967.001]
  • [Cites] Am J Gastroenterol. 2006;101 Suppl 1:S7-12 [16448451.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):14-8 [9987458.001]
  • [Cites] J Infect Dis. 1998 Oct;178(4):954-9 [9806021.001]
  • [Cites] N Engl J Med. 1997 Dec 11;337(24):1733-45 [9392700.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):330-3 [8665183.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] Am J Epidemiol. 1995 Aug 1;142(3):331-41 [7631637.001]
  • [Cites] Epidemiol Rev. 1994;16(2):418-36 [7713187.001]
  • [Cites] West J Med. 1992 Jan;156(1):30-5 [1310362.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Feb;2(2):87-106 [15017613.001]
  • [Cites] Hepatology. 2004 Feb;39(2):476-83 [14768001.001]
  • [Cites] Hepatology. 2003 May;37(5):1114-21 [12717392.001]
  • (PMID = 17444427.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; 9008-11-1 / Interferons; JAC85A2161 / Adenine
  • [Other-IDs] NLM/ PMC2569653
  •  go-up   go-down


33. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J: Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol; 2005 Aug;100(8):1764-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan.
  • OBJECTIVES: We retrospectively compared the usefulness of three different staging systems for hepatocellular carcinoma (HCC), the Cancer of the Liver Italian Program (CLIP) scoring system, the Barcelona Clinic Liver Cancer (BCLC) classification system, and the Japan Integrated Staging (JIS) system, in terms of patient distribution and survival rates.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086713.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kang YK, Hong SW, Lee H, Kim WH: Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog; 2010 Sep;49(9):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of ezrin expression in human hepatocellular carcinoma.
  • The authors investigated ezrin expression in human hepatocellular carcinoma (HCC) and sought to determine its relation with clinicopathologic parameters, patients' outcome, and interacting molecular markers.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers / metabolism. Cadherins. Cytoskeletal Proteins. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasms / pathology. Prognosis. Young Adult


35. Goodman J, Glasgow SC, Schnitzler M, Lowell JA, Shenoy S, Jendrisak MD, Desai N, Lisker-Melman M, Crippin J, Chapman WC: Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease. Arch Surg; 2005 May;140(5):459-64; discussion 464
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease.
  • HYPOTHESIS: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects.
  • PATIENTS: Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation.
  • After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups.
  • RESULTS: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Case-Control Studies. Databases, Factual. Female. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate


36. Jacene HA, Stearns V, Wahl RL: Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med; 2006 Jul;31(7):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT.
  • A 42-year-old African-American female with a history of metastatic breast carcinoma was found to have hypermetabolic porta hepatic, peripancreatic, and paraaortic lymphadenopathy and hypermetabolism in the spleen on a surveillance FDG positron emission tomography/computed tomography (PET/CT) scan.
  • The resolution of the lymphadenopathy and the patient's clinical course led to the conclusion that the most likely explanation for the FDG PET/CT findings was inflammation secondary to acute hepatitis C infection and not metastatic breast carcinoma.
  • Infected macrophages in the lymph nodes draining the liver in this case and stimulation of a cellular immune response by the hepatitis C virus, with resultant cytokine production by cytotoxic and T-helper cells, offer possible explanations for the findings seen on FDG PET/CT in this case.
  • [MeSH-major] Breast Neoplasms. Carcinoma / secondary. Fluorodeoxyglucose F18. Hepatitis C / complications. Lymphatic Diseases / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Abdomen. Acute Disease. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Mastectomy. Radiotherapy, Adjuvant. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / secondary. Spleen / radionuclide imaging. Tamoxifen / therapeutic use. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785802.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Radiopharmaceuticals; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Kim YS, Rhim H, Lim HK, Park CK, Lee WJ, Do YS, Cho JW: Completeness of treatment in hepatocellular carcinomas treated with image-guided tumor therapies: Evaluation of positive predictive value of contrast-enhanced CT with histopathologic correlation in the explanted liver specimen. J Comput Assist Tomogr; 2006 Jul-Aug;30(4):578-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completeness of treatment in hepatocellular carcinomas treated with image-guided tumor therapies: Evaluation of positive predictive value of contrast-enhanced CT with histopathologic correlation in the explanted liver specimen.
  • OBJECTIVE: To evaluate the positive predictive value of contrast-enhanced multiphase computed tomography (CT) in determining the completeness of treatment, after radiofrequency (RF) ablation and/or transcatheter arterial chemoembolization, based on histopathologic correlation in the explanted liver specimen.
  • MATERIALS AND METHODS: During a recent 10-year period, 84 consecutive patients who had a history of RF ablation and/or transcatheter arterial chemoembolization for hepatocellular carcinoma (HCC) underwent liver transplantation in our institution.
  • We investigated the necrosis rate of HCC on the basis of microscopic examinations of the explanted liver specimen and calculated the positive predictive value of CT in determining the completeness of treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / radiography. Liver Neoplasms / therapy. Radiography, Interventional. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Catheter Ablation. Chemoembolization, Therapeutic. Combined Modality Therapy. Contrast Media. Female. Humans. Liver Cirrhosis / complications. Liver Transplantation. Male. Middle Aged. Necrosis. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845287.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Boni J, Abbas R, Leister C, Burns J, Jordan R, Hoffmann M, DeMaio W, Hug B: Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol; 2009 Jul;64(2):263-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Intravenous (i.v.) temsirolimus, a novel inhibitor of mammalian target of rapamycin (mTOR), is approved for treatment of renal cell carcinoma.
  • In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Area Under Curve. Cytochrome P-450 CYP2D6 Inhibitors. Drug Combinations. Drug Interactions. Female. Humans. Injections, Intravenous. Male. Middle Aged. Substrate Specificity. Young Adult

  • Hazardous Substances Data Bank. DESIPRAMINE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015855.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytochrome P-450 CYP2D6 Inhibitors; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 624KN6GM2T / temsirolimus; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; TG537D343B / Desipramine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


39. Nguyen VT, Amin J, Law MG, Dore GJ: Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol; 2009 Mar;24(3):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia.
  • BACKGROUND AND AIM: Incidence and mortality of hepatocellular carcinoma (HCC) has increased markedly over the last three decades in Australia.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Hepatitis B, Chronic / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. New South Wales / epidemiology. Prognosis. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175834.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


40. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, Kojiro M, Ueno T, Yoshimura A, Sata M: Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene; 2006 Oct 5;25(45):6056-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
  • Aberrant activation of the Ras/Raf-1/extracellular-regulated kinase (ERK) pathway has been shown to be involved in the progression of human hepatocellular carcinoma (HCC).
  • Forced expression of Spred-1 inhibited HCC cell proliferation in vitro and in vivo, which was associated with reduced ERK activation.
  • In addition, Spred-1 inhibited growth factor-mediated HCC cell motility.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Intracellular Signaling Peptides and Proteins / physiology. Liver Neoplasms / metabolism. Repressor Proteins / physiology. Signal Transduction / physiology. ras Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Base Sequence. Blotting, Western. DNA Primers. Female. Humans. Immunohistochemistry. Male. Membrane Proteins. Middle Aged. Phenotype. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652141.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Repressor Proteins; 0 / SPRED1 protein, human; 0 / SPRED2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


41. Concejero A, Chen CL, Wang CC, Wang SH, Lin CC, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B, Huang TL, Cheng YF, Eng HL: Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation; 2008 Feb 15;85(3):398-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan.
  • BACKGROUND: Living donor liver transplantation (LDLT) demonstrates certain survival benefits over deceased donor liver transplantation for hepatocellular carcinoma (HCC) but there is no consensus on criteria for the use of LDLT for HCC for hepatocellular carcinoma (HCC) taking into account strategies to improve survival.
  • The median disease severity scores were B, 11-20, and 2B for Child-Turcotte-Pugh, Model for End-stage Liver Disease, and United Network for Organ Sharing, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Transplantation. Living Donors
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Taiwan / epidemiology. Treatment Outcome


42. Saunders D, Seidel D, Allison M, Lyratzopoulos G: Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther; 2010 May;31(10):1051-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence.
  • We examined such evidence for hepatocellular carcinoma.
  • AIM: To review the effect of increased levels of body mass index on hepatocellular carcinoma risk.
  • METHODS: We reviewed systematically the literature examining the association between increased body mass index and hepatocellular carcinoma risk.
  • Seven cohort studies found a positive association between obesity (body mass index > or =30 kg/m(2)) and hepatocellular carcinoma risk (relative risks ranging from 1.4 to 4.1); two reported no association; and one reported a significant inverse association for a population subgroup (relative risk = 0.7, 95% confidence interval: 0.5-0.9).
  • CONCLUSION: Although most studies did not adjust for confounders and most data relate to a single world region, the overall evidence is suggestive of an increased hepatocellular carcinoma risk in obese and overweight individuals.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Liver Neoplasms / complications. Obesity / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Body Mass Index. Female. Humans. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2010 Jul;32(2):304-5 [20636625.001]
  • (PMID = 20175765.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


43. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S, JPHC Study Group: Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer; 2009 Apr 1;124(7):1644-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women.
  • The incidence of hepatocellular carcinoma (HCC) is much higher in men than in women.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Diet / adverse effects. Isoflavones / pharmacology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Male. Middle Aged. Prospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19089922.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoflavones
  • [Investigator] Tsugane S; Inoue M; Sobue T; Hanaoka T; Ogata J; Baba S; Mannami T; Okayama A; Miyakawa K; Saito F; Koizumi A; Sano Y; Hashimoto I; Ikuta T; Miyajima Y; Suzuki N; Nagasawa S; Furusugi Y; Nagai N; Sanada H; Hatayama Y; Kobayashi F; Uchino H; Shirai Y; Kondo T; Sasaki R; Watanabe Y; Miyagawa Y; Kishimoto Y; Takara E; Fukuyama T; Kinjo M; Irei M; Sakiyama H; Imoto K; Yazawa H; Seo T; Seiko A; Ito F; Shoji F; Murata A; Minato K; Motegi K; Fujieda T; Matsui K; Abe T; Katagiri M; Suzuki M; Doi M; Terao A; Ishikawa Y; Tagami T; Sueta H; Doi H; Urata M; Okamoto N; Ide F; Sakiyama H; Onga N; Takaesu H; Uehara M; Horii F; Asano I; Yamaguchi H; Aoki K; Maruyama S; Ichii M; Takano M; Matsushima S; Natsukawa S; Akabane M; Konishi M; Okada K; Saito I; Iso H; Honda Y; Yamagishi K; Sugimura H; Tsubono Y; Kabuto M; Tominaga S; Iida M; Ajiki W; Ioka A; Sato S; Yasuda N; Kono S; Suzuki K; Takashima Y; Maruyama E; Yamaguchi M; Matsumura Y; Sasaki S; Watanabe S; Kadowaki T; Kawaguchi Y; Shimizu H
  •  go-up   go-down


44. Wei YF, Wang HC, Chang YC: Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis. J Formos Med Assoc; 2006 Apr;105(4):346-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis.
  • Hemoperitoneum caused by ruptured hepatocellular carcinoma (HCC) is not uncommon in patients with HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618616.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


45. Zhang GQ, Wang HB, Gao P, Fang CH, Chen GH: [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients]. Zhonghua Wai Ke Za Zhi; 2009 Dec 15;47(24):1857-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients].
  • OBJECTIVE: To study the relationship between extrahepatic metastasis of primary hepatocellular carcinoma and circulative tumor cells in the blood of hepatoma patients.
  • METHODS: The immunomagnetic bead technique was employed to enrich and separate the hepatoma cells in the peripheral blood of preoperative and postoperative hepatoma patients.
  • The relationship between postoperative extrahepatic metastasis and hepatoma cells in peripheral blood cancer cells were analyzed.
  • The circulative tumor cells in the peripheral blood of hepatoma patients were enriched and separated by immunomagnetic bead technique.
  • They were identified as hepatoma cells by AFP immunohistochemistry.
  • Among 30 cases of hepatoma patients, the positive rate of hepatoma cells in the peripheral blood of preoperation and postoperation were 53.3% and 83.3% respectively.
  • CONCLUSIONS: Extrahepatic metastasis of primary hepatocellular carcinoma is obviously correlated to the positive tumor cells and the concentration in the peripheral blood of preoperative patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193401.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


46. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z, Fan D: Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract; 2008 Jul;62(7):1056-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteopontin (OPN) was shown to play an important role in the pathogenesis of various inflammatory and fibrotic processes and elevated in fibrotic liver of mouse model.
  • However, the significance of OPN in hepatitis B virus (HBV)-induced liver cirrhosis (LC) remains unclear and is therefore evaluated in this study.
  • METHODS: Thirty-nine patients with HBV-induced LC, 30 patients with HBV infection but without cirrhosis, 11 patients with HBV-related hepatocellular carcinoma (HCC) and 14 additional healthy controls were enrolled in this study.
  • The OPN level was correlated with the severity of liver damage according to Child-Pugh classification (p = 0.003).
  • [MeSH-major] Hepatitis B, Chronic / complications. Liver Cirrhosis / diagnosis. Liver Cirrhosis / virology. Osteopontin / blood
  • [MeSH-minor] Adult. Biomarkers / blood. Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / virology. Disease Progression. Female. Humans. Liver Neoplasms / blood. Liver Neoplasms / virology. Male. Middle Aged. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537188.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 106441-73-0 / Osteopontin
  •  go-up   go-down


47. Wang J, Lu JP, Tian JM, Wang F, Liu Q, Wang L, Gong JG, Jin AG, Zeng H: [Natural history of small hepatocellular carcinoma: studied by MRI]. Zhonghua Zhong Liu Za Zhi; 2005 Apr;27(4):222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of small hepatocellular carcinoma: studied by MRI].
  • OBJECTIVE: To study natural history of small hepatocellular carcinoma (sHCC) and value of MRI in this research.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Cirrhosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949422.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


48. Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H: Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med; 2008;47(19):1637-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHOD: The study subjects were 1,193 patients with HCV-related chronic liver disease and IFN- or IFN plus ribavirin-induced SVR.
  • The age, male/female ratio, and liver fibrosis stage [(F0-F3)/LC] were 15-83 years, 808/385, and 1106/41, respectively.
  • Patients were followed-up for 8.3 years (range, 0 to 19.0 years) and the incidence of hepatocellular carcinoma was recorded.
  • RESULTS: Hepatocellular carcinogenesis was detected in 23 patients during the follow-up.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferons / therapeutic use. Liver Neoplasms / etiology
  • [MeSH-minor] Adolescent. Age Factors. Aged. Aged, 80 and over. Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Cohort Studies. Female. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Retrospective Studies. Ribavirin / administration & dosage. Ribavirin / therapeutic use. Risk Factors. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827409.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 49717AWG6K / Ribavirin; 9008-11-1 / Interferons
  •  go-up   go-down


49. Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP: Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol; 2009 Jan 21;15(3):300-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.
  • AIM: To search for transcription dysregulation that could (1) differentiate hepatocellular carcinoma (HCC)-free from HCC-related cirrhosis (2) differentiate HCC-free cirrhosis related to HCV from that related to alcohol intake.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver Cirrhosis / etiology. Liver Cirrhosis / genetics. Liver Neoplasms / genetics. Transcription, Genetic
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Gene Regulatory Networks. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Plasminogen / genetics. Plasminogen / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):675-84 [18505913.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] Inflamm Res. 2001 Aug;50(8):383-90 [11556518.001]
  • [Cites] Cytokine. 2001 Aug 21;15(4):175-87 [11563878.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] J Virol. 2003 Jun;77(11):6367-75 [12743294.001]
  • [Cites] Oncogene. 2003 May 15;22(19):3007-14 [12771952.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Hepatology. 2003 Sep;38(3):577-88 [12939584.001]
  • [Cites] Genome Biol. 2003;4(9):117 [12952525.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1126-7 [14552335.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):1004-12 [14642619.001]
  • [Cites] Hepatology. 2004 Feb;39(2):353-64 [14767988.001]
  • [Cites] Hepatology. 2004 Feb;39(2):518-27 [14768006.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):565-74 [14767541.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):336-9 [15288485.001]
  • [Cites] J Virol. 2005 Feb;79(3):1569-80 [15650183.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5054-62 [15958548.001]
  • [Cites] J Hepatol. 2006 Apr;44(4):798-805 [16488507.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3801-9 [16799621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3848-56 [16799626.001]
  • [Cites] Int J Oncol. 2006 Aug;29(2):315-27 [16820872.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1587-91 [16861929.001]
  • [Cites] Hepatology. 2006 Oct;44(4):1003-11 [17006931.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1758-67 [17087938.001]
  • [Cites] Hepatology. 2007 Jan;45(1):53-61 [17187415.001]
  • [Cites] Hepatology. 2007 Jan;45(1):42-52 [17187432.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Lab Invest. 2007 Feb;87(2):173-81 [17318196.001]
  • [Cites] Hepatology. 2007 Mar;45(3):725-34 [17326147.001]
  • [Cites] J Virol. 2007 Oct;81(19):10249-57 [17626077.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1749-58 [18350606.001]
  • [Cites] Curr Med Chem. 2008;15(9):834-43 [18473793.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3176-81 [11306505.001]
  • (PMID = 19140229.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9001-91-6 / Plasminogen
  • [Other-IDs] NLM/ PMC2653326
  •  go-up   go-down


50. Vargas-Serrano B, Domínguez-Ferreras E, Chinchón-Espino D: Four cases of solid pseudopapillary tumors of pancreas: imaging findings and pathological correlations. Eur J Radiol; 2006 Apr;58(1):132-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some patients develop liver metastases in the follow-up that can be resected.
  • Two of the patients, developed on follow-up liver metastases, and peritoneal, hepatic, and nodal metastases, respectively.
  • Resection of liver metastases can prolong the long-term survival of the patients.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377114.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


51. Yamasaki I, Nishimori I, Ashida S, Kohsaki T, Onishi S, Shuin T: Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas; 2006 Nov;33(4):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adult. Female. Health Surveys. Humans. Japan. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Surveys and Questionnaires


52. Abdulkareem FB, Banjo AA, Elesha SO, Daramola AO: Histopathological study of liver diseases at the Lagos University Teaching Hospital, Nigeria (1989-2000). Niger Postgrad Med J; 2006 Mar;13(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological study of liver diseases at the Lagos University Teaching Hospital, Nigeria (1989-2000).
  • OBJECTIVE: We present a retrospective histopathological study of 345 liver biopsies over a 12-year period.
  • The study sought to record the frequencies of the range of histopathological changes observed in liver biopsy specimens.
  • MATERIALS AND METHODS: the materials consisted of slides and paraffin embedded blocks of all liver biopsy specimens received from within and outside the hospital.
  • The three common histopathological diagnoses were hepatocellular carcinoma-33%, chronic hepatitis-17.7%, and liver cirrhosis-17.7%.
  • Thirty per cent of hepatocellular carcinoma was post-cirrhotic.
  • The peak age incidence of chronic hepatitis precedes that of liver cirrhosis and hepatocellular carcinoma by one decade.
  • CONCLUSION: the common forms of liver disease diagnosed histologically are hepatocellular carcinoma, chronic hepatitis and liver cirrhosis.
  • [MeSH-major] Hospitals, University. Liver Diseases / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633378.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


53. Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N, Yamana H: Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus; 2010 Nov;23(8):646-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current study evaluates the role of multimodality therapy in esophageal squamous cell cancer patients with distant organ metastasis.
  • Between February 1988 and January 2007, 80 esophageal squamous cell cancer patients with distant organ metastases were treated at our institution.
  • The metastatic organ was the liver (n= 40), the lungs (n= 33), bone (n= 10), and other (n= 6).
  • There was no difference in the median survival among the sites of organ metastasis, lung, liver, or bone (P= 0.8786).
  • However, these results suggested that multimodality therapy could improve survival of the esophageal squamous cell cancer patients with distant organ metastasis.


54. Kim YK, Kim CS, Lee JM, Chung GH, Chon SB: Efficacy and safety of radiofrequency ablation of hepatocellular carcinoma in the hepatic dome with the CT-guided extrathoracic transhepatic approach. Eur J Radiol; 2006 Oct;60(1):100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of radiofrequency ablation of hepatocellular carcinoma in the hepatic dome with the CT-guided extrathoracic transhepatic approach.
  • PURPOSE: The purpose of this study was to determine the efficacy and safety of radiofrequency (RF) ablation for the treatment of hepatocellular carcinoma (HCC) in the hepatic dome with CT-guided extrathoracic transhepatic approach.
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Catheter Ablation / methods. Liver Neoplasms / radiography. Liver Neoplasms / surgery. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781835.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


55. Yang BM, Kim DJ, Byun KS, Kim HS, Park JW, Shin S: The societal burden of HBV-related disease: South Korea. Dig Dis Sci; 2010 Mar;55(3):784-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cost breakdown by disease was CHB at 465,167 million KRW, cirrhosis at 533,449 million KRW, hepatocellular carcinoma at 863,940 million KRW, and liver transplantation at 74,635 million KRW.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / economics. Female. Health Expenditures / statistics & numerical data. Hepatitis B, Chronic / economics. Humans. Liver Cirrhosis / economics. Liver Neoplasms / economics. Liver Transplantation / economics. Male. Middle Aged. Prevalence. Republic of Korea

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S153-7 [15602164.001]
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S175-8 [15602167.001]
  • [Cites] J Med Virol. 2005 Jun;76(2):194-202 [15834881.001]
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S144-7 [15602162.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):457-62 [12172038.001]
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S136-43 [15602161.001]
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S148-52 [15602163.001]
  • [Cites] Lancet. 1996 Sep 14;348(9029):696 [8806283.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Mar;16(3):301-8 [11339422.001]
  • (PMID = 19333757.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Di Leo E, Magnolo L, Bertolotti M, Bourbon M, Carmo Pereira S, Pirisi M, Calandra S, Tarugi P: Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations. Clin Genet; 2008 Sep;74(3):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some patients are asymptomatic, while others have fatty liver, intestinal fat malabsorption and neurological dysfunctions.
  • We investigated three adult subjects with severe hypobetalipoproteinaemia and a family history of FHBL.
  • Proband FHBL-47 had liver cirrhosis with hepatocarcinoma and a renal carcinoma but no clinical manifestations related to FHBL.
  • In adult subjects, the presence of chronic liver disease and chronic diarrhoea, when associated with severe hypobetalipoproteinaemia, may lead to the diagnosis of Ho-FHBL.
  • [MeSH-minor] Adult. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Pedigree. Phenotype


57. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I, Kanematsu T: Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg; 2010 May;34(5):1034-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.
  • BACKGROUND: Microscopic vascular invasion is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation.
  • METHODS: Study 1 included 229 patients with HCC who underwent curative liver resection between 1991 and 2008; 127 had HCC without microscopic portal venous invasion, and 52 had HCC with microscopic portal venous invasion (MPVI).
  • CONCLUSIONS: Tumor size, macroscopic appearance, and high tumor marker levels are important elements in identifying the group of patients with a low HCC recurrence rate after curative liver resection.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / blood. Portal Vein / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Biomarkers, Tumor / blood. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Protein Precursors / blood. Prothrombin. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatol Res. 2009 Feb;39(2):143-8 [19054149.001]
  • [Cites] J Surg Oncol. 2007 Mar 1;95(3):235-40 [17323337.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):221-8; discussion 228-9 [1656903.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):533-9 [11923610.001]
  • [Cites] Hepatology. 1981 Sep-Oct;1(5):431-5 [7308988.001]
  • [Cites] Liver Transpl. 2002 Sep;8(9):765-74 [12200775.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):99-104 [16440425.001]
  • [Cites] Ann Surg. 2008 Nov;248(5):857-62 [18948815.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):177-82 [11574092.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • (PMID = 20127241.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


58. Kulik LM, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Salem R: Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl; 2005 Sep;11(9):1127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report.
  • Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC.
  • The patient received an orthotopic liver transplant (OLT) 42 days after treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Liver Transplantation. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Hepatectomy. Humans. Injections, Intra-Arterial. Male. Microspheres. Neoplasm Staging

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123954.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


59. Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO: Simplifying the preevacuation testing strategy for patients with molar pregnancy. J Reprod Med; 2007 Aug;52(8):685-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial testing included complete blood count (CBC) (87%), liver function tests (LFT) (63%), thyroid-stimulating hormone (TSH) level (72%), clotting function studies (26%) and chest radiograph (84%).
  • One woman with a palpably enlarged goiter and elevated TSH level was diagnosed with thyroid carcinoma.
  • [MeSH-minor] ABO Blood-Group System. Abortion, Spontaneous / blood. Adolescent. Adult. Blood Cell Count. Chorionic Gonadotropin, beta Subunit, Human / blood. Chorionic Gonadotropin, beta Subunit, Human / urine. Diagnosis, Differential. Female. Humans. Liver Function Tests. Medical Records. Molar. Pregnancy. Retrospective Studies. Vacuum Curettage / methods

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879828.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


60. Kuiper EM, Hansen BE, Adang RP, van Nieuwkerk CM, Timmer R, Drenth JP, Spoelstra P, Brouwer HT, Kuyvenhoven JP, van Buuren HR, Dutch PBC Study Group: Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol; 2010 Dec;22(12):1495-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
  • BACKGROUND: The reported incidence of hepatocellular carcinoma (HCC) among patients with primary biliary cirrhosis (PBC) varies from 0.7-3.8%, whereas in cirrhotic patients the risk is considerably higher.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Cholagogues and Choleretics / therapeutic use. Liver Cirrhosis, Biliary / drug therapy. Liver Neoplasms / etiology. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Mass Screening. Middle Aged. Netherlands / epidemiology. Patient Selection. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21389798.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  • [Investigator] Wagtmans MJ; Robijn RJ; de Vries RA; Leeuwerik PJ; Rasica M; Lückers AE; Rijk MC; Ras GJ; van Deursen CT; van der Hoek EW; de Bruijne JW; van Munster IP; van Ditzhuijzen TJ; Houben MH; Valentijn RM; van der Werf SD; ter Borg F; Beukers R; Lesterhuis W; van Vliet AC; Ponssen HH; Eichhorn RF; van de Vrie W; Witteman BJ; van Aken J; Stronkhorst A; Boekema PJ; Kerbert-Dreteler MJ; de Kan R; Haagsma E; Groen JN; Tan TG; van Berkum FN; Thijs JC; Zwertbroek R; Grool TA; van Hoek B; Koek GH; van Hees PN; de Koning RW; de Sévaux RG; de Boer WA; Biemond P; van Tilburg AJ; den Ouden JW; Kubben FJ; Zeijen RN; Engels LG; Looij BJ; Wolfhagen FH; van Erpecum KJ; Vleggaar FP; Tanis AA; Breed JG; Loffeld BC; van Dobbenburgh OA; Lambert J
  •  go-up   go-down


61. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F: Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab; 2007 Dec;92(12):4590-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
  • CONTEXT: Patients with progressive medullary thyroid carcinoma (MTC) undergo multiple imaging procedures for diagnosis of relapse and staging.
  • Sensitivity of FDG-PET/CT was 83% for neck, 85% for mediastinal, 75% for lung, 60% for liver, and 67% for bone metastases; overall sensitivity was 76%.
  • [MeSH-major] Carcinoembryonic Antigen / immunology. Carcinoma, Medullary / immunology. Carcinoma, Medullary / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Thyroid Neoplasms / immunology. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Bone and Bones / radionuclide imaging. Female. Humans. Image Processing, Computer-Assisted. Iodine Radioisotopes. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Prospective Studies. Radioimmunodetection. Radioimmunotherapy. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878252.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carcinoembryonic Antigen; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM: Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol; 2010 Jul;63(7):599-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
  • AIMS: Glypican 3 (GPC3) is a heparan sulphate proteoglycan that shows elevated levels in the serum of patients with hepatocellular carcinoma (HCC), but not in healthy blood donors or patients with benign liver disease.
  • This study explores the value of GPC3 expression for diagnosis of HCC by immunohistochemistry in liver needle biopsy specimens.
  • METHODS: Archival material of liver needle biopsies from 54 patients with HCC, nine with focal nodular hyperplasia or focal liver cell dysplasia, five with cirrhosis, seven with hepatitis B or unremarkable liver tissue, seven with cholangiocarcinoma, and 30 with metastatic tumours, was retrieved for immunohistochemical staining with GPC3 antibody and appropriate positive and negative controls.
  • In contrast, all 58 non-HCC cases of liver biopsies, including focal nodular hyperplasia, focal liver cell dysplasia, cirrhosis, hepatitis B or unremarkable liver tissue, cholangiocarcinoma and metastatic tumours, were negative for GPC3.
  • CONCLUSIONS: GPC3 is a valuable diagnostic marker for diagnosing HCC on liver needle biopsy.
  • It can be used to distinguish HCC from other benign hepatic conditions and metastatic tumours in the liver.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / diagnosis. Glypicans / analysis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Liver Diseases / diagnosis. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501450.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Neoplasm Proteins
  •  go-up   go-down


63. Hara M, Tanaka K, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S: Case-control study on cigarette smoking and the risk of hepatocellular carcinoma among Japanese. Cancer Sci; 2008 Jan;99(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study on cigarette smoking and the risk of hepatocellular carcinoma among Japanese.
  • Emerging epidemiologic data suggest that cigarette smoking may increase the risk of hepatocellular carcinoma (HCC), yet considerable controversies (e.g. inconsistent dose-response relationships) still exist with this association.
  • We examined whether smoking was associated with HCC risk in a case-control study including 209 incident HCC cases and two different control groups (256 hospital controls and 381 patients with chronic liver disease [CLD] without HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology. Smoking / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Japan / epidemiology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956590.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


64. Ippolito D, Sironi S, Pozzi M, Antolini L, Invernizzi F, Ratti L, Leone EB, Fazio F: Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol; 2010 Jan;73(1):148-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization.
  • PURPOSE: To assess the value of CT-perfusion in determining the quantitative vascularization features of early hepatocellular carcinoma (HCC) in cirrhotic patients.
  • Data were analyzed using a dedicated software which generated a quantitative map of liver parenchyma perfusion.
  • Perfusion values calculated in cirrhotic liver parenchyma were HP: median=10.3 (1(st)qt=9.1; 3(st)qt=13.2); BV: median=11.7 (1(st)qt=9.6; 3(st)qt=15.5); AP: median=10.4 (1(st)qt=8.6; 3(st)qt=11.3); HPI: median=17.5 (1(st)qt=14.3; 3(st)qt=19.7); TTP: median=44.6 (1(st)qt=40.3; 3(st)qt=50.1).
  • HP, BV, HPI and AP were found to be significantly higher in HCC lesion than in liver parenchyma (p<0.001), while TTP was significantly lower (p<0.001).
  • CONCLUSION: CT-perfusion technique allows obtaining quantitative information about tumor-related vascularization of early HCC, in patients with liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Liver Cirrhosis / radiography. Liver Neoplasms / radiography. Neovascularization, Pathologic / radiography. Perfusion Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity


65. Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, König J, Rau B, Schilling M: Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J Gastroenterol; 2006 Nov 7;12(41):6627-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.
  • AIM: To evaluate and compare the expression profiles of CXCL12 (SDF-1), CCL19 (MIP-3beta), CCL20 (MIP-3alpha) and CCL21 (6Ckine, Exodus2) and their receptors on RNA and protein levels in hepatocellular carcinoma (HCC) versus colorectal liver metastases (CRLM) and to elucidate their impact on the carcinogenesis and progression of malignant liver diseases.
  • METHODS: Chemokine expression was analyzed by RT-PCR and ELISA in 11 cases of HCC specimens and in 23 cases of CRLM and corresponding adjacent non-tumorous liver tissues, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Chemokines / metabolism. Colorectal Neoplasms / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CCL20. Chemokine CXCL12. Chemokines, CC / genetics. Chemokines, CC / metabolism. Chemokines, CXC / genetics. Chemokines, CXC / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Macrophage Inflammatory Proteins / genetics. Macrophage Inflammatory Proteins / metabolism. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Predictive Value of Tests. Receptors, CCR6. Receptors, CXCR4 / genetics. Receptors, CXCR4 / metabolism. Receptors, Chemokine / genetics. Receptors, Chemokine / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3833-9 [12839981.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3205-13 [16540672.001]
  • [Cites] Tumour Biol. 2006;27(3):166-74 [16641550.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):161-8 [16706828.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):468-77 [16764701.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):418-28 [12901288.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1885-91 [12970869.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2351-8 [15073111.001]
  • [Cites] Am J Gastroenterol. 2004 Jun;99(6):1111-21 [15180734.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):4929-35 [15470034.001]
  • [Cites] Comput Methods Programs Biomed. 1995 Dec;48(3):257-62 [8925653.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] J Cell Biol. 1998 May 18;141(4):1053-9 [9585422.001]
  • [Cites] J Immunol Methods. 1998 Nov 1;220(1-2):1-17 [9839921.001]
  • [Cites] Clin Immunol. 2005 Feb;114(2):174-82 [15639651.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Cancer J. 2004 Nov-Dec;10(6):374-80 [15701269.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1800-7 [15753377.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2744-53 [15837989.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] J Clin Invest. 2000 May;105(10):1383-93 [10811846.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1706-12 [10959056.001]
  • [Cites] Thromb Res. 2000 Sep 15;99(6):587-94 [10974345.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3530-5 [10999740.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):597-606 [11267967.001]
  • [Cites] Hepatology. 2001 Aug;34(2):311-9 [11481616.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4747-57 [11591806.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2937-41 [12019175.001]
  • [Cites] Jpn J Cancer Res. 2002 Jul;93(7):789-97 [12149145.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1551-8 [12176869.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):186-9 [12673677.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):601-5 [12684696.001]
  • [Cites] Scand J Immunol. 2003 Jun;57(6):534-44 [12791091.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4658-65 [16000558.001]
  • [Cites] Int J Cancer. 2005 Sep 20;116(5):726-33 [15828050.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Aug;20(4):401-9 [16114988.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):117-30 [16125170.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):61-6 [16327980.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2902-14 [16493048.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1910-6 [16622267.001]
  • (PMID = 17075975.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCL20 protein, human; 0 / CCR6 protein, human; 0 / CXCL12 protein, human; 0 / Chemokine CCL20; 0 / Chemokine CXCL12; 0 / Chemokines; 0 / Chemokines, CC; 0 / Chemokines, CXC; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, CCR6; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine
  • [Other-IDs] NLM/ PMC4125667
  •  go-up   go-down


66. Mukherjee E, Mukherji D, Jayawardene SA, Kon SP: Tumor lysis syndrome and acute renal failure--an increasing spectrum of presentations. Clin Nephrol; 2007 Sep;68(3):186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / drug therapy. Humans. Leukemia, Myeloid / drug therapy. Liver Neoplasms / drug therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915624.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact; 2007 May 20;168(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
  • Although they have several important limitations primary human hepatocytes still represent the in vitro gold standard model for xenobiotic metabolism and toxicity studies.
  • The large use of human liver cell lines either from tumoral origin or obtained by oncogenic immortalisation is prevented by the loss of various liver-specific functions, especially many cytochrome P450 (CYP)-related enzyme activities.
  • We review here recent results obtained with a new human hepatoma cell line, named HepaRG, derived from a human hepatocellular carcinoma.
  • Moreover contrary to other human hepatoma cell lines including HepG2 cells, HepaRG cells express various CYPs (CYP1A2, 2B6, 2C9, 2E1, 3A4) and the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) at levels comparable to those found in cultured primary human hepatocytes.
  • They also express various other functions such phase 2 enzymes, apical and canalicular ABC transporters and basolateral solute carrier transporters, albumin, haptoglobin as well as aldolase B that is a specific marker of adult hepatocytes.
  • HepaRG cells could represent a surrogate to primary human hepatocytes for xenobiotic metabolism and toxicity studies and even more, a unique model system for analysing genotoxic compounds.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Models, Biological. Xenobiotics / toxicity
  • [MeSH-minor] Aflatoxin B1 / poisoning. Biomarkers / metabolism. Cell Differentiation. Cell Line, Tumor. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Female. Hepatocytes / cytology. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Inhibitory Concentration 50. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Steroid / genetics. Receptors, Steroid / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241619.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Transcription Factors; 0 / Xenobiotics; 0 / constitutive androstane receptor; 0 / pregnane X receptor; 9035-51-2 / Cytochrome P-450 Enzyme System; 9N2N2Y55MH / Aflatoxin B1
  • [Number-of-references] 23
  •  go-up   go-down


68. Wang QM, Yang KM, Zhou HY, Li X, Yang HJ, Li YS: [The role of beta-catenin in rat embryonic development and tumorigenesis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):872-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the role of beta-catenin as a key element of Wnt/beta-catenin signaling pathway in the development of embryonic liver and liver tumorigenesis.
  • METHODS: Immunohistochemical method was used to examined beta-catenin proteins in 12-day (E12), 16-day (E16) embryonic rat liver, neonate rat liver, and in adult rat liver as well as in rat hepatoma.
  • RESULTS: Beta-catenin proteins were found in cytoplasm of E12 and E16 embryonic liver as well as in hepatoma.
  • The expression level of beta-catenin protein in E12 embryonic liver was higher than that in E16.
  • There were much more positive cells in E12 embryonic liver than in E16.
  • However, no positive cell was observed expressing beta-catenin proteins in neonate rat liver and adult rat liver.
  • CONCLUSION: Wnt/beta-catenin signaling pathway was open during the development of embryonic liver and hepatic tumorigenesis.
  • The accumulation of beta-catenin proteins in cytoplasm of embryonic liver and rat hepatic carcinoma cells might be caused not by the elevation of transcription of beta-catenin gene but by the avoidance of degeneration of beta-catenin protein.
  • [MeSH-major] Liver / embryology. Liver / metabolism. Liver Neoplasms, Experimental / metabolism. Liver Neoplasms, Experimental / pathology. beta Catenin / genetics. beta Catenin / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236583.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


69. Thelen A, Jonas S, Benckert C, Weichert W, Schott E, Bötcher C, Dietz E, Wiedenmann B, Neuhaus P, Scholz A: Tumor-associated lymphangiogenesis correlates with prognosis after resection of human hepatocellular carcinoma. Ann Surg Oncol; 2009 May;16(5):1222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated lymphangiogenesis correlates with prognosis after resection of human hepatocellular carcinoma.
  • However, its significance in hepatocellular carcinoma (HCC) is not well established.
  • METHODS: We analyzed tissue specimens from healthy liver (n = 36), cirrhotic liver (n = 24), and HCC (n = 60) by immunohistochemistry, using antibody D2-40 specific for lymphendothelia.
  • RESULTS: In contrast to healthy as well as cirrhotic liver, lymphangiogenesis was induced in HCC.
  • Tumors with high LVD (24 of 60) had developed significantly more frequently in cirrhotic livers (P = 0.001) and were more frequently restricted to one liver lobe (P = 0.04).
  • CONCLUSIONS: Tumor-associated lymphangiogenesis is involved in neovascularization of hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / physiopathology. Liver Neoplasms / physiopathology. Lymphangiogenesis. Lymphatic Vessels / pathology. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Hepatectomy. Humans. Male. Microvessels / pathology. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224279.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Wen Y, Miao X, Xiong L, Xiong G, Hu J, Zhong D, Li Q, Liu W: Application of hemihepatic vascular occlusion with hanging maneuver in hepatectomy. Hepatogastroenterology; 2009 Mar-Apr;56(90):442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were randomized into 3 groups: Pringle maneuver was applied in Group 1 (n=40), hemihepatic inflow control was Group 2 (n=30) and complete hemihepatic vascular occlusion with hanging maneuver was applied in Group 3 (n=24).The clamping period, operation time, bleeding volume, blood transfusion volume, postoperative recovery of liver function and postoperative complications were compared among three groups.
  • The postoperative serum ALT and total bilirubin (TBIL) in Group 2 and 3 were significantly lower than those of Group 1.5 patients died of liver failure after operation in Group 1.
  • But liver failure or morbidity wasn't happened in Group 2 and 3.
  • CONCLUSION: Hemihepatic vascular occlusion with hanging maneuver, which can reduce bleeding volume and enhance the recovery of liver function, is safe and practicable, especially for patients with liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver / blood supply. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Blood Loss, Surgical / prevention & control. Blood Loss, Surgical / statistics & numerical data. Blood Transfusion / statistics & numerical data. Female. Humans. Liver Function Tests. Male. Middle Aged. Postoperative Complications. Recovery of Function. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579617.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  •  go-up   go-down


71. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R: Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford); 2010 Feb;12(1):56-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.
  • BACKGROUND: To determine factors associated with outcomes and microvascular invasion (MVI) in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC).
  • RESULTS: One hundred and one patients had HCC in the explanted liver; one patient was excluded because of fibrolamellar histology.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Microvessels / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Kentucky. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Odds Ratio. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Tennessee. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2004 Jul;10(7):911-8 [15237377.001]
  • [Cites] Ann Surg. 1985 Oct;202(4):401-7 [2996449.001]
  • [Cites] Surgery. 1991 Oct;110(4):726-34; discussion 734-5 [1656538.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):734-41; discussion 731-43 [7794077.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Transplant Proc. 1997 Feb-Mar;29(1-2):492-4 [9123098.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):479-90 [9790338.001]
  • [Cites] Arch Surg. 2005 Apr;140(4):353-8 [15837885.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1086-92 [16123959.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3640-2 [17175354.001]
  • [Cites] Transpl Int. 2007 Feb;20(2):141-6 [17239022.001]
  • [Cites] Clin Transplant. 2007 Nov-Dec;21(6):696-701 [17988261.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S20-37 [18304676.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):900-5 [18343084.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8 [18422961.001]
  • [Cites] J Gastroenterol. 2009;44 Suppl 19:96-101 [19148801.001]
  • [Cites] J Am Coll Surg. 2000 Oct;191(4):389-94 [11030244.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):25-30; discussion 31 [11146770.001]
  • [Cites] Ann Surg. 2001 May;233(5):652-9 [11323504.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1394-403 [11391528.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Gut. 2002 Jan;50(1):123-8 [11772979.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):224-32; discussion 232 [11992808.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):401-11 [12654567.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):495-511, x [15062658.001]
  • (PMID = 20495646.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2814405
  •  go-up   go-down


72. Han YS, Choi DL, Park JB: Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation--eighteen months of follow-up: a case report. Transplant Proc; 2008 Oct;40(8):2835-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation--eighteen months of follow-up: a case report.
  • Diffuse-type hepatocellular carcinoma (HCC) is a contraindication to liver transplantation (OLT).
  • This 41-years-old man was on the waiting list for OLT owing to hepatitis B virus-related liver cirrhosis and esophageal variceal bleeding.
  • The patient received a deceased donor liver transplantation and his postoperative course was uneventful.
  • However, on pathologic findings, the explanted liver showed malignant cells in most cirrhotic nodules.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis B / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / pathology. Liver Transplantation / pathology. Postoperative Complications / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Male. Treatment Outcome


73. Driss M, Abid L, Mrad K, Dhouib R, Charfi L, Bouzaein A, Ben Romdhane K: Breast metastases from undifferentiated nasopharyngeal carcinoma. Pathologica; 2007 Dec;99(6):428-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast metastases from undifferentiated nasopharyngeal carcinoma.
  • The most common primary tumours metastasising to the breast include melanoma, lymphoma, lung cancer and ovarian cancer, while metastases from head and neck cancer are rare.
  • Metastases from undifferentiated nasopharyngeal carcinoma cancers are extremely rare, and only 3 well-documented cases have been reported in the English literature.
  • We report a fourth case of breast metastases from nasopharyngeal carcinoma confirmed by in situ hybridization, focusing on clinical data as well as radiologic and pathologic features.
  • [MeSH-major] Breast Neoplasms / secondary. Carcinoma / secondary. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / isolation & purification. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416334.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Skrzycki M, Scibior-Bentkowska D, Podsiad M, Czeczot H: [Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. Pol Merkur Lekarski; 2008 Dec;25(150):510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcription factors AP-1 and NF-kappaB control important cell processes like proliferation, apoptosis and differentiation.
  • Materials were obtained from patients with alimentary tract tumors (stomach, liver; colon), diagnosed by routine histopathological examination.
  • RESULTS: In all examined alimentary tract tumors (gastric adenocarcinoma, hepatocellular carcinoma, colorectal adenocarcinoma and liver metastases) we observed changes in AP-1 and NF-kappaB protein level comparing with normal tissues.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205384.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 0 / Transcription Factor AP-1
  •  go-up   go-down


75. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, Salerno MG, Scambia G: Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol; 2008 Dec;199(6):642.e1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
  • STUDY DESIGN: In a consecutive prospective series of 113 advanced ovarian cancer patients, the presence of omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis were investigated by laparoscopy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801470.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


76. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ozdil B: Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J Viral Hepat; 2010 Sep;17(9):668-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma.
  • Functional coding region polymorphism F31I in the Aurora A gene has recently been shown to be associated with several human cancers, but its association with hepatocellular carcinoma (HCC) has yet to be investigated.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genetic Predisposition to Disease. Liver Neoplasms / epidemiology. Polymorphism, Genetic. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Substitution / genetics. Aurora Kinases. Case-Control Studies. Female. Gene Frequency. Humans. Male. Middle Aged. Mutation, Missense

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002563.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


77. Qi DF, Wu KJ, Li X, Zeng GH, Chen WZ: [Treating renal carcinoma with ablation or ablation combined with 125I seed implantation: a report of eleven cases]. Ai Zheng; 2005 May;24(5):587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treating renal carcinoma with ablation or ablation combined with 125I seed implantation: a report of eleven cases].
  • BACKGROUND & OBJECTIVE: Recently, multi-needles radiofrequency ablation and brachyradiotherapy have been used to treat some solid tumors, such as liver cancer and prostate cancer.
  • This study was to explore the feasibility and efficacy of radiofrequency ablation or ablation combined with 125I seed implantation on treating renal carcinoma.
  • 2004, 11 patients with a total of 13 renal carcinoma lesions were treated with ablation or ablation combined with (125)I seed implantation, including 6 cases of renal carcinoma of solitary kidney, 2 cases of renal carcinoma combined with contralateral renal atrophy resulted from ureteric stone, 1 case of bilateral tumor, and 2 cases with general conditions contraindicated to surgery.
  • CONCLUSION: Multi-needles radiofrequency ablation or ablation combined with (125)I seed implantation would be an option in the treatment for patients with renal carcinoma of solitary kidney or bilateral kidney lesions, or for patients can't suffer from surgery.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890103.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


78. Lin Q, Huang MS, Hu B, Dong M, Wen JY, Wu XY: [Serum levels of macrophage migration inhibitory factor and interleukin-8 in hepatocellular carcinoma patients: their correlations with tumor progression and prognosis]. Zhonghua Gan Zang Bing Za Zhi; 2007 Jun;15(6):463-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum levels of macrophage migration inhibitory factor and interleukin-8 in hepatocellular carcinoma patients: their correlations with tumor progression and prognosis].
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Interleukin-8 / blood. Liver Neoplasms / pathology. Macrophage Migration-Inhibitory Factors / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594817.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Macrophage Migration-Inhibitory Factors
  •  go-up   go-down


79. Albores-Saavedra J, Henson DE, Moran-Portela D, Lino-Silva S: Cribriform carcinoma of the gallbladder: a clinicopathologic study of 7 cases. Am J Surg Pathol; 2008 Nov;32(11):1694-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cribriform carcinoma of the gallbladder: a clinicopathologic study of 7 cases.
  • Three patients with high nuclear grade cribriform carcinomas died as a result of the tumor which infiltrated the liver by direct extension; 3 patients with low nuclear grade cribriform carcinomas confined to the gallbladder wall survived 4 to 7 years after cholecystectomy and 1 patient was lost to follow-up.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769339.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Dong Q, Chan HL, Liu Z, Chan DP, Zhang B, Chen Y, Kung HF, Sung JJ, He ML: A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. Biochem Biophys Res Commun; 2008 Oct 3;374(4):773-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities.
  • A1762T and G1764A mutations in the basal core promoter are often present in HBV patients but seldom in asymptomatic carriers, and are highly correlated with the increased risk of HBV-associated hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis B virus / genetics. Hepatitis B, Chronic / complications. Liver Neoplasms / virology. Mutation. Viral Core Proteins / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Genotype. Humans. Male. Molecular Sequence Data. Promoter Regions, Genetic. Risk

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675784.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Core Proteins
  •  go-up   go-down


81. Matsuura S, Aishima S, Taguchi K, Asayama Y, Terashi T, Honda H, Tsuneyoshi M: 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology; 2005 Oct;47(4):382-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1.
  • AIMS: 'Scirrhous' hepatocellular carcinoma (scirrhous HCC) is extremely rare and its characteristics remain unclear.
  • We investigated the clinicopathological and immunohistochemical features of scirrhous HCC, compared with those of ordinary hepatocellular carcinoma (ordinary HCC).
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Hepatocytes / metabolism. Keratins / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178893.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


82. Torres-Rendon A, Roy S, Craig GT, Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer; 2009 Apr 7;100(7):1128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas.
  • Proteins necessary for the normal regulation of the cell cycle include minichromosome maintenance protein 2 (Mcm2) and geminin.
  • A high ratio indicates a short G(1) and a high rate of cell proliferation.
  • Mcm2 and geminin have been scarcely explored in oral epithelial dysplasia (OED) and oral squamous-cell carcinoma (OSCC).
  • Paraffin sections of 41 OED cases that progressed to carcinoma, 40 OED without malignant progression, 38 OSCC and 15 NOM were immunostained with antibodies against Mcm2, geminin and Ki67.
  • In all the OED cases (n=81) the levels of expression of Mcm2 (LI, 73.6), geminin (LI, 24.4) and Ki67 (LI, 44.5) were elevated indicating a constant cell-cycle re-entry.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Cell Cycle Proteins / analysis. Ki-67 Antigen / analysis. Mouth Mucosa / chemistry. Mouth Neoplasms / chemistry. Nuclear Proteins / analysis. Precancerous Conditions / chemistry
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Case-Control Studies. Female. Geminin. Humans. Immunohistochemistry. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] Liver Int. 2006 May;26(4):424-32 [16629645.001]
  • [Cites] J Oral Pathol Med. 2006 Jul;35(6):369-75 [16762018.001]
  • [Cites] J Oral Pathol Med. 2008 Jan;37(1):1-10 [18154571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8956-61 [18579778.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Gut. 2002 Mar;50(3):290-1 [11839701.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Pathobiology. 2001;69(3):150-8 [11872961.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2351-61 [12640120.001]
  • [Cites] Head Neck. 2003 Apr;25(4):267-73 [12658730.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Eur J Biochem. 2004 Aug;271(16):3368-78 [15291814.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] J Pathol. 2004 Oct;204(2):121-30 [15376260.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):253-65 [8175912.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1043-53 [9635433.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):113-36 [9689912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5B):3705-8 [9854481.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • (PMID = 19293805.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2669983
  •  go-up   go-down


83. Soon JL, Jeyaraj PR, Agasthian T: Thoracic complications of radiofrequency ablation of recurrent hepatoma. Ann Acad Med Singapore; 2008 Jan;37(1):75-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic complications of radiofrequency ablation of recurrent hepatoma.
  • INTRODUCTION: Radiofrequency ablation (RFA) for unresectable primary or secondary hepatic malignancies have gained widespread availability and acceptance over the past 5 years.
  • CLINICAL PICTURE: We report a patient with symptomatic right pleural effusion due to a diaphragmatic fistula and another with biliptysis post-RFA, for recurrent hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Diaphragm / physiopathology. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Fistula / etiology. Humans. Male. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265903.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


84. Esen BA, Pinarbasi B, Buyukbabani N, Baykal C, Cizmeci O, Demir K, Acarli K, Kaymakoglu S: Merkel-cell carcinoma arising after liver transplantation: a case report. Transplant Proc; 2005 Dec;37(10):4413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel-cell carcinoma arising after liver transplantation: a case report.
  • Merkel-cell carcinoma is a rare and an aggressive neuroendocrine tumour of the skin that has been reported to be common in transplant recipients.
  • Herein, a 25-year-old woman who developed Merkel-cell carcinoma after liver transplantation is reported.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / surgery. Cholangitis, Sclerosing / surgery. Liver Transplantation / adverse effects. Postoperative Complications / pathology
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome


85. Ko FC, Yeung YS, Wong CM, Chan LK, Poon RT, Ng IO, Yam JW: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int; 2010 Jan;30(1):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
  • BACKGROUND: Deleted in liver cancer (DLC) is a family of tumour suppressors that plays a critical role in hepatocellular carcinoma (HCC).
  • In addition, the functional roles of DLC1 isoforms were addressed using HCC cell lines to examine their abilities to suppress stress fibre formation and HCC cell growth.
  • Underexpression of DLC1alpha at the mRNA level was frequently (52.5%, n=52) observed in the 99 HCCs as compared with the corresponding nontumorous liver tissues.
  • Functionally, DLC1alpha and beta, but not DLC1gamma, were localized at focal adhesions of cells and able to inhibit stress fibre formation and suppress HCC cell growth.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic / genetics. Liver Neoplasms / genetics. Transcription, Genetic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Epigenesis, Genetic. Female. GTPase-Activating Proteins. Humans. Male. Middle Aged. Prognosis. Protein Isoforms. RNA, Messenger / metabolism. Tumor Stem Cell Assay. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874489.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


86. Oyunsuren T, Kurbanov F, Tanaka Y, Elkady A, Sanduijav R, Khajidsuren O, Dagvadorj B, Mizokami M: High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol; 2006 Dec;78(12):1688-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses.
  • To investigate the association between viral infection pattern and hepatocellular carcinoma (HCC), 292 chronic hepatitis patients, including 108 with developed HCC were screened using serological and molecular genetics methods.
  • Liver tumor markers; AFP and PIVKA-II are useful tools for complex HCC-screening and clinical follow-up for chronic hepatitis patients in Mongolia.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / etiology. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Hepatitis D, Chronic / complications
  • [MeSH-minor] Adult. Aged. Female. Hepacivirus / classification. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / classification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Hepatitis Delta Virus / classification. Hepatitis Delta Virus / genetics. Hepatitis Delta Virus / isolation & purification. Humans. Male. Middle Aged. Mongolia / epidemiology. Prevalence

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17063518.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Fernandes ML, Lin CC, Lin CJ, Chen WT, Lin SM: Prospective study of a 'popping' sound during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Vasc Interv Radiol; 2010 Feb;21(2):237-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of a 'popping' sound during percutaneous radiofrequency ablation for hepatocellular carcinoma.
  • PURPOSE: To prospectively evaluate the occurrence of a 'popping' sound during radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) and its association with early tumor progression and patient survival.
  • Primary technique effectiveness was achieved in 97 of the 100 (97%) tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Liver Neoplasms / surgery. Noise. Vibration
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pressure. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Noise.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20031448.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  •  go-up   go-down


88. Bartlett AS, McCall JL, Koea JB, Holden A, Yeong ML, Gurusinghe N, Gane E: Liver resection for hepatocellular carcinoma in a hepatitis B endemic area. World J Surg; 2007 Sep;31(9):1775-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for hepatocellular carcinoma in a hepatitis B endemic area.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver.
  • Treatment options include liver resection, tumor ablation, and liver transplantation.
  • RESULTS: A series of 53 patients were identified, of whom 72% had underlying liver disease, mostly chronic hepatitis B infection.
  • There was a good association between the CLIP score and survival following liver resection.
  • CONCLUSION: These findings confirm that with careful patient selection liver resection for HCC can achieve good long-term patient survival and acceptable risks.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Hepatitis B, Chronic / complications. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. New Zealand / epidemiology. Prospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Gut. 2002 Jun;50(6):881-5 [12010894.001]
  • [Cites] Lancet. 1999 Mar 6;353(9155):797-801 [10459961.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Dig Liver Dis. 2005 Apr;37(4):260-8 [15788210.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(6):456-62 [16365818.001]
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):387-92 [10873361.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):208-17 [12560779.001]
  • [Cites] J Am Coll Surg. 2000 Dec;191(6):657-60 [11129815.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1237-41 [14578862.001]
  • [Cites] HPB (Oxford). 2002;4(2):99; author reply 99-100 [18332933.001]
  • [Cites] N Z Med J. 2001 Nov 23;114(1144):516-9 [11795563.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] N Z Med J. 2005 Jun 24;118(1217):U1532 [15980906.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):536-43 [12677151.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):11-8 [16329080.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD002799 [12804438.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):885-92; discussion 892-3 [14631225.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):671-2 [15798471.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):321-8 [16495695.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):297-302 [8604911.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S153-8 [11821803.001]
  • [Cites] Liver Transpl. 2005 Oct;11(10):1177-80 [16184567.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):198-202 [15609381.001]
  • [Cites] J Fam Pract. 2006 Feb;55(2):155-6; discussion 155 [16451784.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jun;20(6):873-81 [15946134.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 2000 Apr;31(4):840-5 [10733537.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1012-7 [10460635.001]
  • [Cites] Am J Surg. 1992 May;163(5):515-8 [1575310.001]
  • (PMID = 17610112.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Li J, Liu B, Yan LN, Zuo YX, Li B, Zeng Y, Zhang SF, Li FG: Reversal of graft steatosis after liver transplantation: prospective study. Transplant Proc; 2009 Nov;41(9):3560-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of graft steatosis after liver transplantation: prospective study.
  • OBJECTIVE: To determine the risk factors for reversal of liver graft steatosis.
  • PATIENTS AND METHODS: This prospective study included 70 patients (47 men and 23 women) who received steatotic liver grafts between July 2003 and February 2008.
  • Patients were divided into 3 groups according to degree of liver steatosis, as follows: mild (n = 29, group 1), moderate (n = 23, group 2), and severe (n = 18, group 3).
  • RESULTS: The median (SD) degree of steatosis in liver grafts at transplantation was 15.7% (7.3%) in group 1, 26.3% (10.5%) in group 2, and 45.1% (8.3%) in group 3.
  • CONCLUSION: Graft steatosis can be decreased substantially after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Fatty Liver / surgery. Liver Neoplasms / surgery. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Biopsy. Brain Death. Female. Follow-Up Studies. Humans. Liver Diseases / classification. Liver Diseases / surgery. Male. Middle Aged. Postoperative Complications / classification. Postoperative Complications / pathology. Prospective Studies. Tissue Donors / statistics & numerical data


90. Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H: High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol; 2005 Dec;77(4):491-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia.
  • However, there are little or no data on the prevalence and genotype distribution of HBV, HCV, and HDV among patients with chronic liver disease in Mongolia.
  • Therefore, serum samples obtained in 2004 from 207 patients (age, mean+/-standard deviation, 51.0+/-11.9 years) including those with chronic hepatitis (n=90), liver cirrhosis (n=41), and hepatocellular carcinoma (n=76) were tested for serological and molecular markers of HBV, HCV, and HDV infections.
  • Of note, triple ongoing infection was significantly more frequent among patients with hepatocellular carcinoma than among those with chronic hepatitis (63.2% vs. 14.4%, P<0.0001).
  • The 106 HCV RNA-positive samples were typed as genotype 1b (92.5%), 2a (0.9%), or 1b plus 2a (6.6%); mixed infection of two distinct HCV genotypes was found exclusively in the patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis B / epidemiology. Hepatitis C / epidemiology. Hepatitis D / epidemiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Female. Hepatitis B Antibodies / blood. Hepatitis B virus / genetics. Hepatitis B virus / immunology. Hepatitis C Antibodies / blood. Hepatitis Delta Virus / genetics. Hepatitis Delta Virus / immunology. Humans. Male. Middle Aged. Molecular Sequence Data. Mongolia / epidemiology. Prevalence

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, inc.
  • (PMID = 16254981.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB221759/ AB221760/ AB221761/ AB221762/ AB221763/ AB221764/ AB221765/ AB221766/ AB221767/ AB221768/ AB221769/ AB221770/ AB221771/ AB221772/ AB221773/ AB221774/ AB221775/ AB221776/ AB221777/ AB221778/ AB221779/ AB221780/ AB221781/ AB221782/ AB221783/ AB221784/ AB221785/ AB221786/ AB221787/ AB221788/ AB221789/ AB221790/ AB221791/ AB221792/ AB221793/ AB221794/ AB221795/ AB221796/ AB221797/ AB221798/ AB221799/ AB221800/ AB221801/ AB221802/ AB221803/ AB221804/ AB221805/ AB221806/ AB221807/ AB221808/ AB221809/ AB221810/ AB221811/ AB221812/ AB221813/ AB221814/ AB221815/ AB221816/ AB221817/ AB221818/ AB221819/ AB221820/ AB221821/ AB221822/ AB221823/ AB221824/ AB221825/ AB221826/ AB221827/ AB221828/ AB221829/ AB221830/ AB221831/ AB221832/ AB221833/ AB221834/ AB221835/ AB221836/ AB221837/ AB221838/ AB221839/ AB221840/ AB221841/ AB221842/ AB221843/ AB221844/ AB221845/ AB221846/ AB221847/ AB221848/ AB221849/ AB221850/ AB221851/ AB221852/ AB221853/ AB221854/ AB221855/ AB221856/ AB221857/ AB221858/ AB221859/ AB221860/ AB221861/ AB221862/ AB221863/ AB221864/ AB221865/ AB221866/ AB221867/ AB221868/ AB221869/ AB221870/ AB221871/ AB221872/ AB221873/ AB221874/ AB221875/ AB221876/ AB221877/ AB221878/ AB221879/ AB221880/ AB221881/ AB221882/ AB221883/ AB221884/ AB221885/ AB221886/ AB221887/ AB221888/ AB221889/ AB221890/ AB221891/ AB221892/ AB221893/ AB221894/ AB221895/ AB221896/ AB221897/ AB221898/ AB221899/ AB221900/ AB221901/ AB221902/ AB221903/ AB221904/ AB221905/ AB221906/ AB221907/ AB221908/ AB221909/ AB221910/ AB221911/ AB221912/ AB221913/ AB221914/ AB221915/ AB221916/ AB221917/ AB221918/ AB221919/ AB221920/ AB221921/ AB221922/ AB221923/ AB221924/ AB221925/ AB221926/ AB221927/ AB221928/ AB221929/ AB221930/ AB221931/ AB221932/ AB221933/ AB221934/ AB221935/ AB221936/ AB221937/ AB221938/ AB221939/ AB221940/ AB221941/ AB221942/ AB221943/ AB221944/ AB221945/ AB221946/ AB221947/ AB221948/ AB221949/ AB221950/ AB221951/ AB221952/ AB221953/ AB221954/ AB221955/ AB221956/ AB221957/ AB221958/ AB221959/ AB221960/ AB221961/ AB221962/ AB221963/ AB221964/ AB221965/ AB221966/ AB221967/ AB221968/ AB221969/ AB221970/ AB221971/ AB221972/ AB221973/ AB221974/ AB221975/ AB221976/ AB221977/ AB221978/ AB221979/ AB221980/ AB221981/ AB221982/ AB221983/ AB221984/ AB221985/ AB221986/ AB221987/ AB221988/ AB221989/ AB221990/ AB221991/ AB221992/ AB221993/ AB221994/ AB221995/ AB221996/ AB221997/ AB221998/ AB221999/ AB222000/ AB222001/ AB222002/ AB222003/ AB222004/ AB222005/ AB222006/ AB222007/ AB222008/ AB222009/ AB222010/ AB222011/ AB222012/ AB222013/ AB222014/ AB222015/ AB222016/ AB222017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Antibodies; 0 / Hepatitis C Antibodies
  •  go-up   go-down


91. Shoji B, Ikeda F, Fujioka S, Kobashi H, Yasunaka T, Miyake Y, Shiraha H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K: Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease. J Gastroenterol; 2010 Nov;45(11):1172-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease.
  • BACKGROUND: For patients with chronic hepatitis due to hepatitis B virus (HBV), factors predicting hepatocellular carcinoma (HCC) other than high levels of HBV-DNA and alanine aminotransferase (ALT) are needed to prevent HCC development, as many patients with chronic HBV infection fulfill these conditions.
  • METHODS: The study was a systematic cohort analysis of 303 consecutive patients with hepatitis B e-antigen, receiving laparoscopic examination for assessment of liver disease.
  • Significant associations with HCC development were shown for liver cirrhosis, histological activity grade, reddish markings, and older age.
  • CONCLUSIONS: HCC development is associated with older age, male gender, and liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis B, Chronic / complications. Laparoscopy / methods. Liver Neoplasms / virology
  • [MeSH-minor] Adult. Age Factors. Aged. Alanine Transaminase / metabolism. Cohort Studies. Female. Follow-Up Studies. Hepatitis B e Antigens / analysis. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / pathology. Liver Cirrhosis / virology. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Retrospective Studies. Risk Factors. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Okayama University Scientific Achievement Repository. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):123-44 [11218911.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):449-55 [11275885.001]
  • [Cites] Hepatology. 2003 Jan;37(1):19-26 [12500184.001]
  • [Cites] Hepatology. 2001 Sep;34(3):590-4 [11526547.001]
  • [Cites] PLoS One. 2008 Jul 02;3(7):e2573 [18596917.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):546-8 [9073137.001]
  • [Cites] Endoscopy. 1985 Jul;17(4):149-52 [2990886.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1070-8 [18688879.001]
  • [Cites] Hepatology. 2007 Feb;45(2):297-306 [17256741.001]
  • [Cites] Semin Liver Dis. 1999;19(3):297-309 [10518309.001]
  • [Cites] Gastroenterol Jpn. 1983 Dec;18(6):593-8 [6231209.001]
  • [Cites] Lancet. 1987 Oct 17;2(8564):877-80 [2889081.001]
  • [Cites] Gastrointest Endosc. 1990 Jan-Feb;36(1):15-8 [2138105.001]
  • [Cites] Hepatol Res. 2008 Sep;38(9):877-85 [18507692.001]
  • [Cites] Gastrointest Endosc. 1996 Jun;43(6):568-71 [8781934.001]
  • [Cites] J Hepatol. 2006 Oct;45(4):575-83 [16899323.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):263-7 [2416625.001]
  • [Cites] Dtsch Med Wochenschr. 1947 Jun 20;72(23-24):308-13 [20268557.001]
  • [Cites] J Hepatol. 2008 Feb;48(2):335-52 [18096267.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35 [17914972.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Acta Med Okayama. 2005 Oct;59(5):217-24 [16286955.001]
  • [Cites] J Gastroenterol. 2009;44(9):1000-6 [19562250.001]
  • [Cites] Hepatology. 1994 Jun;19(6):1513-20 [8188183.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • (PMID = 20549250.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hepatitis B e Antigens; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


92. Luo BM, Wen YL, Yang HY, Zhi H, Ou B, Ma JH, Pan JS, Dai XN: Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology. World J Gastroenterol; 2005 Apr 28;11(16):2402-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology.
  • AIM: To investigate the value of contrast-enhanced C3-MODE technology in differentiating malignant nodules of liver from the benign ones.
  • The vascularities of the liver nodules in the two phases were combined for differential diagnosis.
  • RESULTS: By C3-MODE technology, 33 of the 46 liver nodules were demonstrated as defected area in the late phase and were diagnosed as malignant tumors.
  • Of them, 28 with hypervascularity in the early arterial phase were assessed as hepatocellular carcinoma, the other five nodules with rim-like enhancement in the early arterial phase were diagnosed as metastatic tumors.
  • Corresponding to the pathological results, the sensitivity, specificity and accuracy of contrast-enhanced C3-MODE technology in differentiating malignant and benign nodules in the liver were 97.0%, 92.3% and 95.7%, respectively.
  • CONCLUSION: Contrast-enhanced C3-MODE technology can effectively differentiate malignant liver tumors from the benign nodules.
  • We suggest that it provides a new approach for differential diagnosis of liver nodules in addition to contrast-enhanced CT.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrastructure. Fatty Liver / ultrasonography. Liver Neoplasms / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrastructure. Adult. Aged. Biopsy. Contrast Media. Diagnosis, Differential. Female. Hemangioma / pathology. Hemangioma / ultrasonography. Hepatitis B / pathology. Hepatitis B / ultrasonography. Humans. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832408.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC4305625
  •  go-up   go-down


93. Wang YC, Chen YL, Yuan RH, Pan HW, Yang WC, Hsu HC, Jeng YM: Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis; 2010 Sep;31(9):1516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma.
  • Here, we report that Lin-28B, but not Lin-28, is highly expressed in hepatocellular carcinoma (HCC).
  • Knockdown of Lin-28B by RNA interference in the HCC cell line HCC36 suppressed proliferation in vitro and reduced in vivo tumor growth in NOD/SCID mice.
  • In contrast, overexpression of Lin-28B in the HCC cell line HA22T enhanced tumorigenicity.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Apoptosis. Blotting, Western. Cell Adhesion. Cell Movement. Cell Proliferation. Gene Expression Regulation, Neoplastic. HMGA2 Protein / genetics. HMGA2 Protein / metabolism. Humans. Male. Mice. Mice, Inbred NOD. Mice, SCID. MicroRNAs / genetics. MicroRNAs / metabolism. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Xenograft Model Antitumor Assays. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20525879.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / LIN-28 protein, human; 0 / Lin-28 protein, mouse; 0 / MIRN98 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


94. Hu S, Li Y, Liu G, Song Q, Wang L, Han Y, Zhang Y, Song Y, Yao X, Tao Y, Zeng H, Yang H, Wang J, Zhu H, Chen ZN, Wu L: A protein chip approach for high-throughput antigen identification and characterization. Proteomics; 2007 Jun;7(13):2151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a new approach to produce high-quality mAbs against human liver proteins using a combined force of high-throughput mAb production and protein microarrays.
  • After immunizing mice with live cells from human livers, we isolated 54 hybridomas with binding activities to human cells and identified the corresponding antigens for five mAbs via screening on a protein microarray of 1058 unique human liver proteins.
  • Among them, we discovered that eIF1A expressed only in normal liver tissues, not in hepatocellular carcinoma in humans.
  • [MeSH-minor] Adult. Animals. Antigens, CD147 / analysis. Antigens, CD147 / immunology. Antigens, CD147 / metabolism. Biomarkers / analysis. Carrier Proteins / analysis. Carrier Proteins / immunology. Eukaryotic Initiation Factor-1 / analysis. Eukaryotic Initiation Factor-1 / immunology. Eukaryotic Initiation Factor-1 / metabolism. Female. Humans. Immunohistochemistry. Liver / chemistry. Liver / metabolism. Liver Diseases / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Membrane Proteins / analysis. Membrane Proteins / immunology. Membrane Proteins / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Proteins / analysis. Neoplasm Proteins / immunology. Neoplasm Proteins / metabolism. Nuclear Proteins / analysis. Nuclear Proteins / immunology. Reproducibility of Results. Vaccination

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549792.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens; 0 / BSG protein, human; 0 / Biomarkers; 0 / Carrier Proteins; 0 / Eukaryotic Initiation Factor-1; 0 / FGL1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / ORMDL2 protein, human; 0 / PIR protein, human; 0 / Proteins; 0 / eukaryotic peptide initiation factor-1A; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


95. Morohashi S, Odagiri H, Morohashi H, Kimura Y, Sasaki M: Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab. Breast Cancer; 2007;14(3):297-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
  • A 32-year-old woman underwent modified radical mastectomy for right breast cancer (invasive ductal carcinoma, f, INF beta, v0, ly1, pT2, pN1, M0, Stage II B ER (+/-), PR (-), Her2 (3+)) in June 2003, and received postoperative systemic adjunctive chemotherapy using epirubicin combined with cyclophosphamide, followed by paclitaxel.
  • In August 2004, after a disease-free interval of 14 months, liver metastasis appeared, and therefore from September 2004, combination chemotherapy with oral capecitabine (2,400 mg/day) and injected trastuzumab (120 mg/week) was started.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Injections, Intravenous. Trastuzumab


96. Delektorskaia VV, Perevoshchikov AG, Golovkov DA, Kushlinskiĭ NE: [Immunohistochemical study of E-cadherin, beta-catenin and CD-44v6 expression in the cells of primary colon cancer and its metastases]. Arkh Patol; 2005 Nov-Dec;67(6):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study of E-cadherin, beta-catenin and CD-44v6 expression in the cells of primary colon cancer and its metastases].
  • 129 primary colon carcinomas, 35 metastases to the lymph nodes and 92 metastases to the liver are studied.
  • Reduction or complete absence of E-cadherin was more frequently observed in cases with liver metastases (64/ 84 - 76%) than in patients without metastases (14/45 - 31%) (p = 0,014).
  • [MeSH-major] Antigens, CD44 / biosynthesis. Cadherins / biosynthesis. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glycoproteins / biosynthesis. Liver Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405020.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen; 0 / Cadherins; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / beta Catenin
  •  go-up   go-down


97. Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S, Furukawa K, Mitsuhashi N, Takeuchi D, Suda K, Yoshioka I, Miyazaki M: Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. J Hepatobiliary Pancreat Surg; 2007;14(4):358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification.
  • BACKGROUND/PURPOSE: The role of aggressive surgery for stage IV gallbladder carcinoma remains controversial.
  • METHODS: A retrospective analysis was done of 79 patients with JSBS stage IV gallbladder carcinoma who had undergone surgical resection with curative intent at our institution.
  • RESULTS: In the patients with stage IV gallbladder carcinoma, the curative resection rate was 65.8% and the hospital mortality rate was 11.4%.
  • Neither hepatic invasion nor liver metastasis was a significant factor.
  • [MeSH-major] Carcinoma / surgery. Gallbladder Neoplasms / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Neoplasms / secondary. Biliary Tract Neoplasms / surgery. Female. Follow-Up Studies. Hospital Mortality. Humans. Japan. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging / methods. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653633.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


98. Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, Scolastico C, Onofrio M, Imparato M, Filippini P: The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol; 2005 Apr;75(4):522-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.
  • Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data.
  • In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy.
  • A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC).
  • These findings indicate that nearly one quarter of patients with chronic liver diseases in Italy have a severe disease such as liver cirrhosis and HCC represents a not negligible burden for the national health system.
  • Hepatitis C is the important pathogenic factor for chronic liver disease in Italy.
  • [MeSH-major] Hepatitis C / complications. Liver Diseases / epidemiology. Liver Diseases / etiology
  • [MeSH-minor] Adult. Aged. Alcoholism / complications. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / etiology. Chronic Disease / epidemiology. Female. Hepacivirus. Hepatitis B / complications. Hepatitis B / epidemiology. Hepatitis B virus. Humans. Incidence. Italy / epidemiology. Liver Cirrhosis / epidemiology. Liver Cirrhosis / etiology. Liver Neoplasms / epidemiology. Liver Neoplasms / etiology. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15714480.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


99. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer; 2007 Mar;43(4):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
  • Tumour-associated trypsin inhibitor (TATI) overexpresses in various tumours, but its clinicopathological significance in hepatocellular carcinoma (HCC) is unclear.
  • By RT-PCR in the linear range, TATI was found to be overexpressed in 176 of 258 unifocal primary HCCs (68%).
  • Ectopic expression of TATI led to enhanced anchorage-independent tumour cell growth in vitro.
  • We conclude that TATI overexpression contributes to cell growth advantage, enhances the metastatic potential of tumours and leads to advanced HCC with PV invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Portal Vein. Trypsin Inhibitor, Kazal Pancreatic / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. HeLa Cells / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Osteopontin / metabolism. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267202.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 106441-73-0 / Osteopontin; 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic
  •  go-up   go-down


100. Ariizumi S, Kotera Y, Katagiri S, Yamamoto M: Favorable long-term surgical outcomes of hepatocellular carcinoma in patients with hepatitis B envelope antibody. J Surg Oncol; 2010 May 1;101(6):471-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable long-term surgical outcomes of hepatocellular carcinoma in patients with hepatitis B envelope antibody.
  • BACKGROUND: Surgical outcome of patients with hepatocellular carcinoma (HCC) in relation to the serum hepatitis B envelope (HBe) has not been clarified in detail.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / surgery. Hepatitis Antibodies / blood. Hepatitis B virus / immunology. Liver Neoplasms / immunology. Liver Neoplasms / surgery. Viral Envelope Proteins / immunology
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20401917.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis Antibodies; 0 / Viral Envelope Proteins
  •  go-up   go-down






Advertisement